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2. ABBREVIATIONS
ABI ankle-brachial index 
AFS amputation-free survival
ASA asetylsalicylic acid
BMI body mass index (kg/m2) 
CAD coronary artery disease
CKD chronic kidney disease
CI confi dence interval




DSA digital subtraction angiography
eGFR estimated glomerular fi ltration rate (mL/min1.73m2) 
ESRD end stage renal disease
HR hazard ratio 
HUCH Helsinki University Central Hospital 
HUSVasc Vascular registry of Helsinki University Central Hospital
IBS infrainguinal bypass surgery
IC intermittent claudication
LDL low-density lipoprotein
MDR Pa multi-drug resistant Pseudomonas aeruginosa
ns not signifi cant
P. aeruginosa Pseudomonas aeruginosa 
PAD peripheral arterial disease
PTA percutaneus transluminal angioplasty
PVR pulse volyme recording 
ROC-curve receiver operating characteristic curve 
SE standard error
s-cr serum creatinine (μmol/L)
TASC Trans-Atlantic Inter-Society Consensus
TP toe systolic pressure
UTWCS University of Texas Wound Classifi cation System




Amputation-free survival Period from the IBS to the fi rst major amputation of the leg 
on which bypass was performed, or death from any cause, 
whichever occurred fi rst
Complete ulcer healing time Time required from IBS to achieve complete epithelialization of 
the ischaemic tissue defects and the incisional wounds
Failed graft A permanently occluded bypass graft
Freedom from any further
revascularisation
No new bypasses have been performed after the primary 
revascularisation (i.e. freedom from surgical revascularisation) 
or interventions to support the primary revascularisation (i.e. 
maintenance procedures) 
Freedom from surgical 
revascularisation
No new bypass operations have been performed after the primary 
revascularisation
Infrainguinal bypass Arterial reconstruction using a bypass conduit that originates at 
or below the inguinal ligament and ends at a more distal site
Ischaemic tissue defect/loss Ischaemic ulcer or gangrene
Leg salvage Preservation of the leg and ankle. Avoidance of a major 
amputation.
Maintenance procedures Surgical or endovascular interventions performed to support 
patency of the bypass graft or endovascularly revascularised 
arterial segment
Major amputation Amputation above the ankle
Multidrug resistant Pseudo-
monas aeruginosa
Pseudomonas aeruginosa resistant to ciprofl oxacin, tobramycin, 
and a combination of piperacilline and tazobactam
Local ulcer surgery Operations performed on the ischaemic tissue defects







A nonoccluded graft or arterial segment
A graft is considered to have “primary patency” as long as the 
patency is uninterrupted
“Assisted primary patency” includes maintence procedures 
performed to preserve graft patency. Lasts until the graft 
occludes. 
A graft is considered to have “secondary patency” until the graft 
is permanently occluded or when more than half of the bypass 
and both anastomoses are replaced
The whole period of time with a patent infrainguinal bypass graft 
in a leg. The time interval between graft failure and redo bypass 
surgery is not included in “tertiary patency”.
Patency – leg salvage gap Difference between leg salvage rate and graft patency rate. The 
gap decribes the proportion of leg salvage not attributable to 
verifi ed graft patency.
Primary infrainguinal bypass The fi rst infrainguinal bypass to a leg
Redo bypass surgery A completely new infrainguinal bypass graft or replacement 
of more than half of the old infrainguinal graft and both 
anastomoses
Ulcer healing time Time required after IBS to achieve complete epithelialization of 
the ischaemic tissue defects 
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4. ABSTRACT
Background: Atherosclerosis in the peripherial arteries is the most frequent 
cause of inadequate bloodfl ow in the leg. The arterial insuffi ciency may 
ultimately lead to critical leg ischaemia (CLI), i.e. rest pain or tissue loss, or 
both. It is generally agreed that a critically ischaemic leg is at risk for amputation 
unless some improvement of the arterial supply is undertaken. According 
to the latest Trans Atlantic Inter-Society Consensus recommendations, an 
infrainguinal bypass operation is the gold standard treatment for CLI caused 
by extensive infrainguinal arterial occlusions.
There is a widespead reporting habit of combining the outcomes for patients 
with rest pain (Fontaine III) and tissue loss (Fontaine IV) under the single 
category of critical leg ischaemia. Patients with ischaemic tissue loss have 
very seldom been examined separately.
 
Aim of the study: The aim of this study was to evaluate the outcome after 
infrainguinal bypass surgery (IBS) in patients suffering from the most severe 
form of peripheral arterial disease, critical leg ischaemia with tissue loss 
(Fontaine IV).
 
Patients and methods: This study was divided into six parts. All patients 
included in the study were treated at Helsinki University Cental Hospital 
(HUCH) in 2000-2007. First, complete ulcer healing time and comorbidities 
infl uencing it were prospectively assessed in 148 patients undergoing 
IBS for ischaemic tissue loss. Second, the association between local ulcer 
characteristics and ulcer healing time was analysed in a prospective cohort 
study comprising 110 patients treated with IBS. Third, long-term amputation-
free survival (AFS) and risk factors for adverse events were retrospectively 
analysed in 636 patients who underwent IBS for CLI with tissue loss. Fourth, 
the need and results of redo IBS were retrospectively evaluated in 593 patients 
undergoing primary IBS for CLI with tissue loss. Fifth, the outcome of IBS 
was retrospectively compared with endovascular treatment (PTA) of the 
infrapopliteal arteries in 1023 CLI patients. Sixth, the infl uence of a specifi c 
risk factor, multidrug resistant Pseudomans aeruginosa (MDR Pa) bacteria 
in CLI patients treated with IBS during an outbreak in a vascular ward was 
retropectively assessed. Sixty-four patients with positive MDR Pa -culture 
were matched with 64 MDR Pa negative controls.
Main results: Complete ulcer healing rate was 40% at 6 months after IBS 
and 75% at one year. At one year, half of the patients were alive with salvaged 
leg and completely healed ulcers. Diabetes was a risk factor for prolonged 
complete ulcer healing time. At 1 year 63% of diabetics and 87% of non-
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diabetics achieved complete ulcer healing (p = 0.001). The location of the 
ischaemic tissue defects infl uenced ulcer healing time. Tissue defects in the 
mid- and hindfoot healed poorly.
Patients treated with IBS for ischaemic tissue loss showed high leg salvage 
rates but low survival in long-term follow-up. Leg salvage, survival and AFS 
were 83%, 71% and 55% at one year, and 76%, 38% and 30% at fi ve years. 
Age, coronary artery disease, chronic pulmonary disease, gangrene and renal 
insuffi ciency were independent risk factors for decreased AFS. Redo IBS with 
new grafts yielded tertiary patency rates which were superior to secondary 
graft patency rates; 82% vs. 75% at one year and 70% vs. 61% at fi ve years, 
p = 0.003. There was not a signifi cant gap between tertiary patency and leg 
salvage rates, p = 0.281.
In the overall series, endovascular treatment and bypass surgery for CLI 
achieved similar 5-year leg salvage, survival and AFS rates, whereas freedom 
from surgical revascularisation was higher after bypass surgery (94% vs. 86%, 
p < 0.001). In propensity-score-matched pairs, outcomes for bypass and PTA 
did not differ, except for freedom from surgical revascularisation which was 
signifi cantly higher in the bypass group (91% vs. 85% at 5 years, p = 0.045). 
The MDR Pa outbreak infl uenced the short-term AFS in CLI-patients 
undergoing IBS. At one year, only 52% of the patients with MDR Pa 
contamination were alive without amputation whereas 75% of the patients in 
the control group were alive with a salvaged leg (p = 0.020).
Conclusions: Complete healing of ischaemic tissue lesions is a slow 
process, especially in diabetics, even after a successful infrainguinal bypass 
operation. Ischaemic tissue lesions located in mid-and hindfoot healed poorly. 
The absence of gap between tertiary patency and leg salvage indicates the 
importance of a patent infrainguinal graft for saving a leg with ischaemic 
tissue loss. When both PTA and bypass is feasible, infrapopliteal PTA as a 
fi rst-line strategy is expected to achieve similar long-term results to bypass 
surgery in CLI when redo surgery is actively utilized. MDR Pa in a patient 
with CLI should be considered as a serious event with high risk of early major 
amputation or death. IBS for ischaemic tissue loss resulted in high leg salvage 
but the life expectancy of the patients was short. Patients with ischaemic tissue 
loss should be treated as high-risk patients.
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5. INTRODUCTION
Atherosclerosis of the peripheral arteries is the fundamental process in the 
pathogenesis of critical leg ischaemia (CLI). The gradually developing 
occlusive lesions impair the arterial blood fl ow. When bloodfl ow is inadequate 
to provide vital oxygen and nutrients to the leg, a cascade of pathophysiologic 
events that ultimately lead to rest pain or trophic lesions, or both, are 
initiated. 
It is generally agreed that in CLI the viability of the leg is endangered and 
there is risk for amputation unless some improvement of the arterial supply is 
undertaken.
CLI is a growing problem in an aging population (Taylor 2008). As a growing 
proportion of the population lives longer, it is realistic to expect more 
elderly patients to be referred to vascular surgeons for CLI management 
(Lepäntalo and Mätzke 1996, Ballotta et al. 2010). In CLI the viability of the 
leg is endangered, and there is risk for limb loss unless the arterial supply is 
improved. The presence of ischaemic tissue defects seems to be associated 
with poorer prognosis than rest pain alone (Wolfe and Wyatt 1997, Dormandy 
et al. 1999, Taylor et al. 2009). No pharmacologic therapy has demonstrated 
to be effi cient enough in reversing the extensive arterial occlusive lesions and 
symptoms in CLI-patients (Schanzer and Conte 2010). The treatment of CLI is 
one of the most important tasks of vascular surgery. An active revascularisation 
policy has been shown to be associated with decreased major amputation rates 
(Holstein et al. 2000, Luther et al. 2000, Eskelinen et al. 2004), and is likely to 
be cost-effective in terms of salvaging legs and sustaining ambulatory status 
of the patients (Luther 1997). Patients with unacceptable surgical risks due to 
multiple comorbidities, advanced tissue loss, or no identifi able target vessel as 
well as non-ambulatory patients will not gain any benefi t from revascularisation 
and may be considered for palliative medication or amputation (Luther 1997, 
Biancari et al. 2000, Schanzer and Conte 2010). 
When considering all the advances in surgical care over the past 60 years, 
the progress toward leg salvage surgery has been remarkable. Jean Kunlin from 
France was the fi rst to describe the successful use of autogenous vein to bypass 
atherosclerotic occlusion of the superfi cial femoral artery in 1949 (Yao and 
Pearce 1995). The extension of bypass grafts beyond the popliteal trifurcation 
began after John McCaughan Jr described the exposure of the distal popliteal 
artery in 1961. Since then, bypass grafting has gradually been extended to 
arteries at the ankle level and to the foot arteries. The improvement of surgical 
technology including instruments, sutures and lighting, was important for 
performing bypass operations to small arteries. (Conte et al. 2001, Taylor et 
al. 2008). The improvement of imaging techniques and anesthetic care also 
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contributed to the possibility of performing distal bypasses.
Traditionally, open surgical bypass of an occluded arterial segment had 
long been the only effective treatment strategy for limb revascularisation 
in patients with CLI. In 1964 Dotter and Judkins described percutaneous 
transluminal angioplasty (PTA) of the superfi cial femoral artery. The evolution 
of endovascular procedures has increased the treatment options of CLI during 
the past decades. The role of endovascular treatments for CLI patients has 
become an issue of increasing interest, but it is also a source of controversy 
(Bradbury et al. 2002). High-level evidence on which to base treatment 
decisions of CLI patients is still partially lacking (Schanzer and Conte 2010). 
CLI almost always presents a pattern of accelerated, extensive, multilevel 
arterial occlusive disease of the infrainguinal arteries (Bradbury 2003, Van 
Damme 2004). According to the latest Trans-Atlantic Intersociety Consensus 
(TASC) document, an infrainguinal bypass operation is still the gold standard 
treatment for extensive infrainguinal arterial occlusions (Norgren et al. 
2007).
 
Most studies on CLI have combined the outcome for patients with rest pain 
and tissue loss. The outcome in patients with ischaemic tissue loss has very 
seldom been studied separately (Seeger et al. 1999, Taylor et al. 2009). 
As ischaemic tissue loss seems to be a more advanced form of the disease 
than ischaemic rest pain alone, it is reasonable to believe that the outcome 
after infrainguinal bypass grafting in these two patient groups may not be 
similar. Research has shown that CLI patients with ischaemic tissue loss often 
experience prolonged morbidity after IBS (Nicoloff et al. 1998, Goshima et al. 
2004, Nguyen et al. 2006, Taylor et al. 2009). Comorbidities and advanced age 
may complicate recovery from leg salvage surgery. In addition, re-operations 
after arterial reconstruction are often needed (Belkin et al. 1995, Albäck and 
Lepäntalo 1998, Conte et al. 2006). The relatively poor 5-year survival of the 
CLI-patients, typically about 40-70%, underscores the fragile nature of this 
patient group (Wolfe and Wyatt 1997, Norgren et al. 2007, Bradbury et al. 
2010).
The purpose of this study was to evaluate the outcome after infrainguinal 
bypass surgery (IBS) in patients with the most severe form of peripheral 
arterial disease, CLI with tissue loss (Fontaine IV).
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6. REVIEW OF THE LITERATURE
ATHEROSCLEROTIC DISEASE
Atherosclerosis is a systemic disease affecting the whole arterial tree. Atheroma 
is derived from the Greek athere, meaning porridge or gruel whereas sclerosis 
means induration or hardening. The pathogenesis leading to the formation 
of an atherosclerotic plaque is not completely understood. Atherosclerosis 
seems to be a degenerative process of the vessel wall, which is promoted 
by chronic infl ammation and a disturbed endothelial function (Mitchell 
and Sidawy 2005). Monocytes migrate from the blood into the intima and 
transform into macrophages, that accumulate lipids to form the core of the 
atherosclerotic plaque. Production of infl ammatory mediators stimulates 
the proliferation of smooth muscle cells in the intima and the deposition of 
extracellular matrix, which leads to plaque expansion and the formation of 
the fi brous cap. The growth of the plaque is initially directed towards the 
adventitia and subsequently towards the lumen of the vessel. This process may 
result in stenosis and obstruction of the arteries with superimposed thrombosis 
resulting in decreased blood fl ow. Atherosclerosis develops many years before 
any clinical symptoms are manifest (Leng and Fowkes 2001). When arterial 
blood fl ow is signifi cantly compromised, it causes symptoms of ischaemia, 
and at that stage atherosclerosis is already advanced. 
PERIPHERAL ARTERIAL DISEASE
Peripheral arterial disease (PAD) is defi ned as atherosclerosis in the 
arteries distal to the aortic bifurcation, with or without symptoms in the 
legs. Symptoms in the leg the can proceed from an asymptomatic stage to 
intermittent claudication (IC) manifested as muscular pain on exercise. When 
blood fl ow to a leg is insuffi cient to meet the tissue demands of oxygen and 
nutritients at rest, the patient will perceive ischaemic rest pain or develop 
ulcers or gangrene. Chronic ischaemic rest pain and tissue loss are the most 
severe forms of PAD and are classifi ed as critical leg ischaemia (CLI) (Second 
European Consensus Document on Critical Leg Ischaemia 1992). The clinical 
manifestations of ischaemia were fi rst categorised by Fontaine (Fontaine et 
al. 1954). Asymptomatic disease (Fontaine stage I) or claudication (Fontaine 
stage II) seldom leads to amputation (Dormandy et al. 1999), whereas in 
rest pain (Fontaine stage III) and tissue loss (Fontaine stage IV) the leg is 
threatened.
The progression of atherosclerosis from an asymptomatic stage to CLI is 
variable and unpredictable (Dormandy et al. 1999). Most claudicants achieve 
stabilization of the symptoms probably due to the development of collaterals 
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and metabolic adaptation of ischaemic muscle. Approximately 25% of patients 
with IC deteriorate in terms of clinical stage. CLI can also appear without 
preceding IC (Mäzke and Lepäntalo 2001). The extensive comorbidities that 
accompany CLI in many patients may restrict their activities suffi ciently to 
preclude any claudication before CLI. 
CO-EXISTING ATHEROSCLEROTIC DISEASE
Atherosclerosis is a systemic disease with predominance for coronary, carotid 
and lower limb arteries. Coronary artery disease (CAD), cerebrovascular 
disease (CVD) and PAD commonly occur together. The clinical manifestations 
of atherosclerosis have been reported to occur with different frequencies, but 
always with considerable overlap (Aronow and Ahn 1994, CAPRIE Steering 
Committee 1996, Bhatt et al. 2006) (Figure 1). In the primary care setting, half 
of the patients diagnosed with PAD also have CAD and CVD (Norgren et al. 
2007). In PAD patients who are referred to hospital, the prevalence of CAD 
is likely to be higher. The concomitant occurrence of CAD or CVD appears 
to increase with the severity of PAD (Newman et al. 1993, Dormandy et al. 
1999). 
Figure 1. Prevalence of coronary heart disease (CAD) and cerebrovascular disease 
(CVD) in patients with peripheral arterial disease (PAD) (ankle-brachial index ≤ 0.9). 
The weighted means have been calculated from the CAPRIE-study (CAPRIE Steering 
Committee 1996), the REACH-study (Bhatt et al. 2006) and from the study by Aronow 
and Ahn (1994). Modifi ed from the Finnish Current Care Guideline for peripheral arterial 
disease (2010).
DEFINITION OF CRITICAL LEG ISCHAEMIA
There is no complete consensus regarding the vascular hemodynamic 
parameters required to make the diagnosis of CLI. Although the ankle-brachial 
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index (ABI) is used extensively in epidemiological studies and clinical practice, 
there is no precise cut-off point that is diagnostic for PAD or CLI (Hiatt et al. 
1995, Newman et al. 2003). The most frequently used cut-off point for PAD 
is ABI ≤ 0.9 (TASC Working Group 2000, Finnish Current Care Guideline 
Working Group for peripheral arterial disease 2010). The fi rst classifi cation 
of PAD, which is still in use, is the Fontaine classifi cation introduced in 1954 
(Fontaine et al. 1954). More precise criteria for critical leg ischaemia, based 
both on symptoms and pressure measurements, have been developed (Table 
1). The lack of consensus in defi ning CLI partly explains differing results 
achieved in the studies of CLI-patients.
DIAGNOSIS OF CLI
Patient history combined with physical examination is the cornerstone when 
evaluating patients with leg ischaemia. The foot of a critically ischaemic leg 
is usually pale, cold and cyanotic. No pulses can be palpated in the foot. If 
present, the ischaemic tissue defects are usually located distal to the ankle 
although they can be crural as well. The ischaemic tissue lesions may be 
gangrenous, and if not infected, can form an echar, shrink and mummify. 
Although CLI is a clinical diagnosis, it should be confi rmed objectively by 
ankle-brachial index (ABI), toe pressures (TP), or transcutaneous partial 
pressure of oxygen (TcPO
2
). 
Imaging of the lower limb arteries is indicated whenever any 
revascularisation procedure is indicated. The current options for imaging are 
colour-assisted duplex ultrasonography, magnetic resonance angiography, 
computed tomography angiography and digital subtraction angiography 
(DSA). DSA is considered as the gold standard imaging technique. Potential 
side effects and contraindications should be considered when choosing the 
imaging modality, in addition to local availability, experience and cost.
DIFFERENTIAL DIAGNOSIS OF CHRONIC TISSUE DEFECTS IN A LEG 
The prevalence of leg ulcerations in Europe has been estimated to range from 
0.1% to 4.3% (Briggs and Closs 2003). The range of diseases and conditions 
with the potential for chronic leg ulceration is broad and the aetiology may be 
multifactorial (Finnish Current Care Guideline for chronic leg ulcers 2007). 
Arterial insuffi ciency is the aetiology in 9- 22% of chronic leg ulcers (Briggs 
and Closs 2003). The most common cause is venous disease, ranging from 
37% to 76%, and 7- 26% of patients with chronic leg ulcers have combined 
arterial and venous insuffi ciency. The wide variation of the prevalence 
can be explained by the choice of age group in the sample, approaches to 
patient identifi cation, and the number of other aetiology groups included. 
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Table 1. Defi nitions of critical leg ischaemia.
1) Fontaine Classifi cation 1954 (Fontaine et al. 1954)
- Stage III: Rest pain caused by arterial insuffi  ciency
or
- Stage IV: Ulceration and/or gangrene caused by arterial insuffi  ciency 
2) International Vascular Symposium Working Party Defi nition 1982 (Bell et al. 
1982)
- Severe rest pain requiring repeated analgesia for at least four weeks 
and ankle pressure < 40 mm Hg
or
- Ankle pressure < 60 mm Hg in the presence of tissue necrosis or digital gangrene
(diabetics should be defi ned as a separate category)
3) European Consensus Document on Critical Limb Ischaemia 1989
- Severe rest pain requiring opiate analgesia for at least two weeks 
or
- Ulceration or gangrene 
and 
- Ankle pressure < 50 mm Hg 
4) Second European Consensus Document 1992
- Persistently recurring ischaemic rest pain requiring analgesia for at least two weeks 
and ankle systolic pressure < 50 mm Hg and/or toe systolic pressure (TP) < 30 mmHg
or
- Ulceration or gangrene of the foot or toes and ankle systolic pressure < 50 mm Hg or 
TP < 30 mm Hg
5) Criteria of Ad Hoc Committee (revised version) 1997 (Rutherford et al. 1997)
- Grade II, category 4: Ischaemic rest pain and resting ankle pressure < 40 mm Hg, fl at 
or barely pulsatile ankle or metatarsal pulse volume recording (PVR) or TP < 30 mg Hg
or
- Grade III, category 5: minor tissue loss and resting ankle pressure < 60 mm Hg, fl at or 
barely pulsatile ankle or metatarsal PVR or TP < 40 mg Hg
or
- Grade III, category 6: major tissue loss extending above metatarsal level, functional 
foot not salvageable and resting ankle pressure < 60 mm Hg, fl at or barely pulsatile 
ankle or metatarsal PVR or TP < 40mmg Hg
6) Trans Atlantic Inter-Society Consensus for the management of peripheral arterial 
disease 2000 (TASC Working Group 2000)
- Clinical defi nition: chronic, ischaemic rest pain, ulcers, or gangrene attributable to 
objectively proven arterial occlusive disease
- Defi nition for trials: ankle pressure < 50 - 70 mm Hg or TP < 30 - 50 mm Hg or 
trancutaneous partial pressure of oxygen (TcPO2 ) < 30 –50 mm Hg
7) Trans Atlantic Inter-Society Consensus for the management of peripheral arterial 
disease (TASC II) 2007 (Norgren et al. 2007)
- Chronic ischaemic rest pain and ankle systolic pressure < 50 mm Hg or TP < 30 mm Hg
or
- Ulcer or gangrene and ankle systolic pressure < 70 mm Hg or TP < 50 mm Hg
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The prevalence of leg ulcers shows an exponential rise with increasing age. 
Neuropathic ulcers typically occur on weightbearing surfaces. Neuropatic, 
ischeamic and metabolic factors may contribute foot ulcers in diabetics. 
Pressure ulcers may occur in bed-ridden patients. Tissue defect in a leg may 
be posttraumatic. Less frequent aetiologies of chronic leg ulcers include 
connective tissue diseases (e.g. systemic lupus erythematosus, scleroderma, 
calcifylaxia and rheumatoid arthritis), vasculitis (e.g. polyarteritis nodosa and 
Wegener’s granulomatosis), pyoderma gangrenosum and neoplastic diseases 
(e.g. basal cell carcinoma, squamous cell carcinoma and melanoma). 
INCIDENCE OF CLI
CLI itself is diffi cult to assess on population bases, and most estimates are 
indirect. The only large prospective population study on the incidence of CLI 
identifi ed 220 new CLI-cases every year/million population (Rothwell et al. 
2005). 
The indirect estimates are not exact since they are dependent on the selected 
population, the activity of vascular surgery in the region and the CLI criteria 
used. Indirect estimates have been made using major amputation rates, or 
derived from hospitalizations for CLI and from the calculated risk for patients 
with IC to develop CLI. Estimates of CLI have varied between 300 to 1000/
million/year when calculations have been perforemd using one or several 
of the indirect methods (Catalano 1993, The Vascular Surgical Society of 
Great Britain 1995, TASC Working Group 2000). None of these studies have 
estimated the incidences separately for rest pain and tissue loss. (Figure 2).
Figure 2. The iceberg of peripheral arterial disease. The prevalence of PAD and CLI in 
a Finnish population. Only a small amount of patients with PAD will present clinically. 
Modifi ed from Leng and Fowkes (2001) and the Finnish Current Care Guideline for 
peripheral arterial disease (2010).
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RISK FACTORS FOR CLI
Risk factors for the development of PAD and CLI have not been studied as 
widely as the other two major manifestations of atherosclerosis, coronary artery 
disease and cerebrovascular disease (Donnelly and Yeung 2002). Undisputable 
risk factors for CLI include age, diabetes and smoking (TASC Working Group 
2000, Finnish Current Care Guideline Working Group for peripheral arterial 
disease 2010) (Figure 3). Although the various factors described in this 
section are usually referred to as risk factors, there is only evidence for an 
association (Dormandy et al. 1999). The criteria used to support a risk factor 
require a prospective controlled study showing that altering the factor alters 
the development of the course of the disease. Risk factors have a greater than 
additive effect on the overall risk (Murabito et al. 1997, Donnelly and Yeung 
2002).
Figure 3. Approximate assessment of magnitude of various risk factors for developing 
CLI. Modifi ed from Dormandy et al. (1999), TASC II (Norgren et al. 2007) and Finnish 
Current Care Guideline for peripheral arterial disease (2010).
Diabetes
Diabetes is one of the main risk factors for PAD and it is the most important 
aetiology in the development of CLI (Dormandy et al. 1999, Norgren et al. 
2007, Finnish Current Care Guideline Working Group for peripheral arterial 
disease 2010). In patients with diabetes, each 1% increase in hemoglobin 
A
1c
 causes a corresponding increase of 28% in the risk of PAD (Adler et al. 
2002). In diabetics, the arterial occlusive disease primarily affects the crural 
arteries, while the pedal vessels remain patent (Da Silva et al. 1996, Graziani 
et al. 2007). PAD in patients with diabetes is more aggressive compared to 
nondiabetics. Diabetic patients are at least fi ve times more likely to develop 
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CLI than non-diabetic patients (Second European Consensus Document 1992, 
Norgren et al. 2007). The prevalence of diabetes among patients with leg 
salvage surgery for CLI varies between 30-80%, whereas the prevalence of 
diabetes in comparable age groups in the population is around 10% (Weiss and 
Sumpio 2006, Malmstedt et al. 2008). 
Approximately 15% of all diabetics will develop a foot ulcer during their 
lifetime (Pendsey 2010). Although the aetiology behind diabetic foot ulceration 
is multifactorial, the basic factor preventing healing is often inadequate 
circulation. According to a study by Moulik and et al. (2003) 24% of the diabetic 
foot ulcers are ischaemic, 16% neuroischaemic, 45% neuropathic, and 15% 
have other causes than ischaemia or neuropathy. Recently the international 
EURODIALE Study emphasised the role of ischaemia (Prompers et al. 2008). 
The EURODIALE Study Group reported that 48% of diabetics with foot ulcer 
have leg arterial insuffi ciency. Motoric neuropathy weakens the foot muscles, 
which may result in foot deformity (Bowering 2001, Pendsay 2010). The 
abnormal bony prominences are prone to develop ulcers in weight bearing 
areas. The lack of protective sensation due to sensoric neuropathy exacerbates 
the development of ulcerations. Autonomic neuropathy causes opening of 
arteriovenous shunts, which decreases nutritive blood fl ow and manifest with 
warm skin, sometimes falsely reassuring the clinician. Autonomic neuropathy 
leads to diminished sweating and makes the overlying skin dry and susceptible 
to fi ssures. The combination of hyperglycemia and ischaemia impairs the 
defence mechanisms. Infection may spread extremely rapidly in a diabetic 
foot, and it may lead to life-threatening general septic infection if treatment 
is delayed (Vuorisalo et al. 2009). The risk for amputation at metatarsal or 
higher level due to arterial insuffi ciency is eight-fold in diabetics compared 
to non-diabetics over 45 years (Johannesson et al. 2009). Especially young 
patients with type I diabetes have a very high risk for a non-traumatic major 
amputation compared to non-diabetics; the risk was 86-fold below the age of 
65 years in the study by Jonasson et al. (2008).
Smoking
Smoking is the most important modifi able risk factor for CLI. The effect 
of smoking on the prevalence of symptomatic PAD has varied between 
1.4 and 10.2 depending on the study (Willingendahl et al. 2004). There is 
a clear dose-response relationship, with a strong increase in risk for PAD 
in heavy smokers (Fowkes et al. 1992, Murabito et al.1997, Willingendahl 
et al. 2004). Smokers with PAD are much more likely to progress to CLI 
than non-smokers (Dormandy et al.1999). The number of cigarettes smoked 
per day has also been associated with peripheral graft occlusion, increased 
risk of amputation, and mortality (Lassila and Lepäntalo 1988, Galaria et al. 
2005). Stopping smoking slows the progression of the disease and relieves 
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the symptoms, but not immediately upon cessation (Collinson and Donnelly 
2006). Stopping smoking seems the most benefi cial action the patient can 
take to prevent CLI.
Age
There is clear evidence from several large studies that increasing age is 
associated with increased risk for PAD (Fowkes et al. 1992, Murabito et 
al. 1997, Criqui 2001, Diehm et al. 2004, Kennedy et al. 2005). The risk of 
PAD has been reported to increase 1.5-2.0-fold for every ten years rise in 
age (Fowkes et al. 1992, Murabito et al.1997). Age is also associated with 
the progression of PAD to CLI (Newman et al. 1993, Dormandy et al.1999). 
According to a recent Swedish study, severe leg ischaemia occurred in 0.3% in 
the age group of 60 to 64 years, the prevalence increased with increasing age 
and was highest (3.3%) the age group of 80 to 84 years (Sigvant et al. 2007).
Dyslipidemia
Several studies have shown a relationship between dyslipidemia and CAD but 
the relationship between dyslipidemia and CLI is not quite as clear (Finnish 
Current Care Guideline Working Group for dyslipidemia 2010). Indeed, the 
role of dyslipidemia in the atherosclerosis of peripheral arteries does not seem 
to be as signifi cant as in coronary and carotid arteries. In the Framingham 
study, a fasting cholesterol level greater than 7 mmol/L was associated with a 
doubling of the incidence of IC (Kannel 1994). In the Framingham study the 
ratio of total to high-density lipoprotein cholesterol turned out to be a better 
predictor of occurrence of PAD than total cholesterol alone. No randomised 
studies of good quality have been published indicating that hyperlipidemia 
increases the progression of PAD to CLI. There is some evidence that the 
treatment of hyperlipidemia reduces the progression of PAD (Pedersen et 
al. 1998, Heart Protection Study Collaborative Group 2002). It is worth to 
note that in addition to the lipid-lowering effect, statins seem to have anti-
infl ammatory effects, ability to modulate thrombogenesis and they also provide 
plaque stabilization (Rosenson et al. 1999, Xu et al. 2004, Rice and Lumsden 
2006). It has also been suggested that there is an association between PAD and 
hypertriglyceridemia. Abnormal triglyceride concentrations often accompany 
conditions, such as diabetes mellitus type 2 and metabolic syndrome, which in 
themselves are risk factors for PAD and CLI (Stalenhof and de Graaf 2008). 
Most lipid lowering guidelines recommend treatment as secondary prevention 
for anyone with increased risk for coronary heart disease, including those with 
PAD (Fourth Joint Task Force of The European Society of Cardiology and 
other Societies on Cardiovascular Disease Prevention in Clinical Practise 2007, 
Finnish Current Care Guideline Working Group for dyslipidemia 2009). 
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Hypertension
Hypertension and PAD often occur together, but their relationship is not clear 
(Finnish Current Care guideline Working Group for peripherial arterial disease 
2010). Most intervention trials in hypertension have not included lower-limb 
endpoints (Donnelly and Yeung 2002). In the Edinburgh Artery Study, the 
severity of hypertension paralleled the severity of PAD (Fowkes et al. 1992). 
Hypertension is probably both a cause and an effect of atherosclerosis (Leng 
and Fowkes 2001). Athrosclerosis may cause hypertension due to reduced 
arterial compliance and increased peripheral resistance thereof. Tight control 
of blood pressure in PAD-patients, the main purpose of which is to reduce the 
risk of stroke and coronary heart disease, is an important aspect of secondary 
prevention (Norgren 2007, Finnish Current Care Guideline Working Group 
for Hypertension 2009).
Chronic renal insuffi ciency
Since chronic kidney disease and PAD share many risk factors, it is not 
surprising that the prevalence of PAD is high in patients with chronic renal 
insuffi ciency (Luo et al. 2010). Diabetes mellitus and hypertension are frequent 
causes of nephropathy and uremia is often accompanied by a dyslipidemic 
serum profi le (Cunningham 1995). Chronic renal failure is known to accelerate 
atherosclerosis. The prevalence of PAD increases as the renal function 
measured by glomerular fi ltration rate (eGFR) decreases (Luo et al. 2010). 
Nephropathy constitutes an additional threat to the patient in terms of lower 
limb complications including infection and amputation (Hill et al. 1996) and 
mortality (Biancari et al. 2000, Albers et al. 2007).
Thrombophilia
Thrombophilia has long been recognized as contributing to venous thrombosis. 
So far, the infl uence of thrombophilia on arterial disease has not been thorougly 
investigated (Burns et al. 2001). It is possible, that it has a more important role 
in PAD and its progression to CLI what has been presumed. As there are a 
variety of processes likely to promote thrombus formation, comprehensive 
screening tests are not obtainable and the true prevalence of thrombophilia 
cannot readily be calculated. (Vig et al. 2004). Thrombophilic alterations may 
be an aggravating factor when arterial stenosis is present (Sartori et al. 2010). 
Several studies have found increased homocysteine levels in PAD-patients 
(Darius et al. 2003, Sofi  et al. 2003, Khandapour et al. 2009). Higher levels 
of fi brinogen and antiphospholipid antibodies have been reported in patients 
with CLI as compared to controls (Sartori et al. 2010). In the study by Foley et 
al. (1997) the prevalence of factor V Leiden mutation was fi ve-fold in patients 
undergoing IBS compared with to a local population. Sofi  and colleagues (2003) 
noted a correlation between the number of altered thrombophilic parametes 
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and the Fontaine stages. In young patients (under 51 years old) undergoing leg 
revascularisation, as many as 76% may have a hypercoagulable state (Eldrup-
Jörgensen et al. 1989). So far, none of the thrombophilic alterations have been 
clearly identifi ed as independent risk factor for CLI and there is no evidence 
to suggest that the treatment of thrombophilia will alter the progression of 
peripheral arterial occlusive disease (Burns et al. 2001). There is evidence 
however, that patients with thrombophilia undergoing revascularisation have 
a poorer prognosis, with a three-fold increased risk of graft thrombosis (Vig et 
al. 2004), and this can partially be offset by treatment of thrombophilia (Burns 
et al. 2001). 
FATE OF A PATIENT WITH CLI
The natural history of critical leg ischaemia cannot be studied without bias, 
as the majority of patients will be subjected to different kinds of treatment. 
Treatment largely depends on the centre to which the patient is referred (Luther 
et al. 2000, Bradbury et al. 2002). Large surveys in the 1980s and 1990s 
suggested that approximately half of the patients with CLI will undergo some 
form of revascularisation, while one quarter receive medical treatment only, 
and one quarter will require a primary amputation (Dormandy et al. 1999). 
During the last decades, revascularisation options in CLI have increased. In 
some, particularly active, interventional centres as many as 90% of patients 
with CLI will have an attempt of revascularisation (Norgren et al. 2007). 
Studies have showed that patients with CLI have a 20% mortality rate 
during the fi rst year after presentation and the scarce long-term data that exist 
suggest that the mortality rate continues to be high (The i.c.a.i Group 1997, 
Wolfe and Wyatt 1997, Norgren et al. 2007) (Figure 4). Patients not suitable 
for active treatment are the group providing the least biased data of the natural 
outcome of CLI. They do not represent the whole CLI group because a large 
portion of the patients have such poor general condition or the arteriosclerosis 
is so widespread, that arterial reconstruction is not possible. However, some 
conclusions about the outcome of CLI can be drawn from patients who have 
not undergone revascularisation for various reasons. Lepäntalo and Mätzke 
(1996) studied the outcome of 105 patients with 136 critically ischaemic 
legs that were treated conservatively. Reasons not to revascularise were; 
the extensive nature of the arterial disease alone or in combination with an 
increased operative risk in 54%, operative risk alone in 33%, borderline CLI 
in 7%, and patient preference in 6% of the patients. At one year, 54% of the 
patients had died, and 46% undergone a major amputation, whereas 28% of 
the patients were alive with a non-amputated leg. The one-year survival of an 
age and sex adjusted population would have been 93%. Separate outcome data 
for patients with tissue loss was not reported. Jivegård et al. (1995) reported a 
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leg salvage rate of 45% and amputation-free survival rate of 33% at 18 months 
in a group of CLI patients who were treated conservatively. Patients with 
advanced ischaemia, for example, gangrene of more than one toe or extensive 
ischaemic ulcers were excluded from the study. 
Figure 4. Mean survival curves of patients with peripheral arterial disease (IC=intermittent 
claudication, CLI=critical leg ischeamia) and matched controls (Norgren et al. 2007).
Although not substantiated by an adequate prospective study, the presence 
of ischaemic ulceration and gangrene (Fontaine IV) seems to be associated 
with a poorer prognosis than rest pain (Fontaine III) alone. According to 
estimatates by Dormandy et al. (1999), 95% of patients who present with 
ischaemic gangrene and 80% of patients with rest pain, are dead within 10 
years. In the study by Joint Vascular Research Group in Britain (Wolfe 1986), 
patients with CLI who had an ischaemic ulceration or gangrene were twice as 
likely to require a major amputation as those with rest pain alone. In a review 
by Wolfe and Wyatt (1997), CLI patients were divided into two groups: the 
low-risk group included patients with rest pain and ankle pressures above 
40mmHg, and the high-risk group with tissue loss or ankle pressure below 
40mmHg. At one year, 27% of the patients in the low risk group achieved leg 
salvage without revascularisation, the corresponding portion being 5% in the 
high-risk group. 
Marston et al. (2006) studied patients with chronic superfi cial ulcerations 
who were not candidates for revascularisation. 86 of the 169 legs (51%) 
fulfi lled the TASC criteria (TASC Working Group 2000) for CLI. Marston 
and colleagues reported that ABI correlates with the risk of limb loss. At one 
year 43% of limbs with ABI < 0.4 had required major amputation as compared 
to 15% if ABI was 0.5-0.7. Ulcer healing rate for the whole group was 52% at 
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one year. Survival data were not reported.
Tautenhahn et al. (2008) analysed 53 patients with Fontaine IV disease 
who received conservative treatment because no revascularisation procedure 
was deemed possible. Twenty patients were excluded either because they had 
primary amputation or they died during their fi rst hospital stay for CLI. The 
fi nal series included 33 patients. After 6 months of conservative treatment, 
40% of the leg ulcers had healed. The amputation rate in the small series by 
Tautenhahn et al. was 37% at 5 years. Mortality rates were not reported.
TREATMENT OPTIONS OF CLI
All patients with ulcers, gangrene, or pain in the foot that are possibly related 
to CLI should be considered urgent cases and referred to a vascular surgical 
unit (TASC Working Group 2000, Lepäntalo et al. 2000). The primary goal of 
the treatment of CLI is revascularisation, the purpose of which is to provide 
suffi cient blood fl ow to relieve ischaemic symptoms and to allow healing of 
ischaemic tissue defects. 
Randomised trials have been diffi cult to justify in a fi eld where amputation 
is considered to be the alternative to revascularisation. Defi nitive high-level 
evidence on which to base treatment decisions is still lacking (Beard 2008, 
Schanzer and Conte 2010). The Second European Consensus Document 
(1992) proposed that a reconstructive procedure should be attempted if there 
is a 25% chance of saving a useful limb for the patient for at least one year. 
That recommendation may be too liberal as it ignores the natural outcome 
of CLI (Lepäntalo and Mätzke 1996). For patients who tolerate surgical or 
endovascular revascularisation, these are the preferred treatments as they 
may offer the best chance for limb salvage (Norgren et al. 2007, Varu 2010). 
Both Pomposelli et al. (1990) and Faglia et al. (1998) have emphasised the 
importance of the restoration of a pedal pulse and forefoot perfusion particularly 
in diabetics and in patients with tissue loss. Traditionally, open surgical bypass 
has been the only effective treatment strategy for limb revascularisation in 
CLI. However, during the past decades, the introduction and evolution of 
endovascular procedures has signifi cantly increased treatment options. Despite 
technical and clinical advances, some patients have such extensive arterial 
disease in the leg that vascular reconstruction is impossible (Schanzer and 
Conte 2010). Treatment decisions in CLI are based on the clinical status of the 
leg, fuctional status, anatomy of the arterial occlusive lesions, and surgical risk. 
The TASC II Working Group has published recommendations for the treatment 
of PAD in the femoropopliteal region (Norgren et al. 2007) (Table 2). These 
recommendations provide some evidence for those with either the mildest or 
the most severe disease patterns. There are no corresponding recommendations 
for the treatment of atherosclerotic lesions in the crural arteries. 
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Table 2. Summary of the classifi cation of femoropopliteal lesions and treatment 








TASC A Single stenosis ≤10 cm in length or
Single occlusion ≤10 in length
Endovascular
TASC B Multiple lesions (stenosis or occlusions) 
each ≤ 5 cm or
Single stenosis or occlusion ≤ 15 cm not 
involving the infrageniculate popliteal 
artery or
Single or multiple lesions in the absence 
of continuous tibial vessels to improve 
infl ow to a distal bypass or




TASC C Multiple stenosis or occlusions totaling > 
15 cm with or without heavy calcifi cation 
or
Recurrent stenosis or occlusions that 
need treatment after two endovascular 
interventions
Surgery for low risk patients, 
endovascular for high-risk 
patients
TASC D Chronic total occlusions of common 
or superfi cial femoral artery (> 20 cm, 
involving the popliteal artery) or 
Chronic total occlusions of popliteal 
artery and proximal trifurcation vessels
Surgery
Infrainguinal bypass surgery
According to the latest TASC recommendations, IBS is the gold standard for 
the treatment of long multisegmental arterial lesions (Norgren et al. 2007) 
(Table 2). The majority of patients with CLI have multisegmental disease, 
and an increasing proportion of them are diabetics, whose arterial disease 
primarily affects the infrapopliteal arteries (Da Silva et al. 1996, Bradbury 
2003, Graziani et al. 2007).
A fundamental principle of infrainguinal bypass surgery is the requirement 
for unimpeded arterial infl ow at the proximal anastomosis of the graft (Conte 
2009). The least diseased distal artery with the best continuous run-off to the 
foot should be used for outfl ow. 
The preferred conduit for an infrainguinal bypass is the autogenous great 
saphenous vein (Van Damme 2004, Schanzer et al. 2007, Conte 2009). In its 
absence another vein of good quality maybe used. Lesser saphenous vein or arm 
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(cephalic and basilic) veins are autogenous vein conduit options. The vein grafts 
may be implanted in reversed, non-reversed, or in situ bypass confi gurations. 
Large series demonstrate comparable results for patency of the different vein 
confi gurations (Shah et al. 1995, Belkin et al. 1996, Schanzer et al. 2007), and the 
choice is affected primarily by surgeon preference and anatomic circumstances. 
Dacron and polytetrafl uoroethylene are the most popular synthetic graft materials. 
Synthetic conduits are more dependent on outfl ow resistance and less tolerant 
of low fl ow states, leading to poor patency rates as compared with autogenous 
conduits (Panayiotopoulos and Taylor 1997). Johnson et al. (2000) reported 
the initial performance of the prosthetic grafts to be similar to vein grafts, but 
during long-term follow up, the vein bypasses fared better even in the above-knee 
position. Interposition of a vein cuff at the distal anastomosis has been reported to 
improve patency rates of prosthetic grafts in the below-knee position (Stonebridge 
et al. 1997). Various coatings are under active research by the vascular graft 
industry. Heparin-bonded prosthetic grafts appear to give prolonged patency 
rates compared to ordinary prosthesis (Lindholt et al. 2011). Long-term data have 
demonstrated the patency of autologous vein grafts to crural and pedal targets for 
10 years in signifi cant percentages of patients (Shah et al. 1995, Ballotta et al. 
2008), validating the biologic capacity of vein as a small artery substitute. Patients 
with ischaemic tissue lesions have greater risk for surgical wound infection than 
patients with intact skin (Bandyk 2008). As vein grafts are more resistant to 
infection than prosthesis, they are preferred especially when treating patients with 
ischaemic tissue loss (Bandyk and Esses 1994). Adequate tissue coverage of the 
graft is important (Seeger et al. 1999). Prosthetic or other non-autogenous conduits 
should be considered inferior choices for infrainguinal bypasses in CLI patients 
(Faries et al. 2000, Pereira 2006, Norgren et al. 2007). The reasons for using 
prosthetic grafts include a lack of suitable veins due to varicosities, postphlebitic 
changes, small vein calibre, previous IBS or coronary bypass surgery with venous 
grafts or previous varicose vein surgery or severe comorbidities that do not allow 
an extended surgcical procedure. 
Percutaneous transluminal angioplasty 
Percutaneous puncture of an artery makes the introduction of long catheters 
into the vessel lumen possible, allowing angiography and endovascular 
procedures to be performed (Ayerdi and Hodgson 2005). The atherosclerotic 
lesions are crossed with a guide wire using a luminal or subintimal technique. 
Balloon dilatation with or without supporting mesh metal tubes (stents) is 
the basic method used to dilatate or open up stenosed or occluded vessels. 
An increasing number of techniques for endovascular therapy have become 
available, including laser angioplasty, cryoplasty and excisional atherectomy, 
thereby expanding the extent and type of lesions amenable for endovascular 
treatment (DeRubertis et al. 2007). 
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Percutaeous transluminal angioplasty (PTA) was recommended for stenosis 
and bypass for arterial occlusions in the fi rst TASC Document published in 
2000. In the second TASC Document (2007), PTA was still recommended for 
stenosis and bypass for long occlusions, but there was no consensus on short 
and moderate occlusions (Table 2). Patency rates are affected by the lesion 
treated and the outfl ow vessels (Conrad et al. 2009). Short stenoses give 
better results than long occlusions and a good run-off gives better patency 
rates than a poor run-off. As a result of endovascular device evolution and 
advances in the techniques, together with growing experience, endovascular 
therapy for infrapopliteal arterial disease is gaining wider acceptance. A 
recent meta-analysis including 30 studies of infrapopliteal angioplasty as 
treatment for CLI patients reported the pooled estimate of technical success 
to be 89% (Romiti et al. 2008). Procedural complication rate of 7-10% have 
been reported (Haider at al. 2006, DeRubertis et al. 2007, Romiti et al. 2008). 
The most frequent complication is bleeding from the puncture site. Other 
complications include pseudoaneurysms, thrombosis, distal embolization, 
dissections, vessel perforation, cardiac complications and renal failure. The 
need for repeated interventions may be seen as a limitation of the technique. 
Restenosis rates have been as high as 50% at one year (Mlekusch et al. 2002) 
and 65% at 2 years (Haider et al. 2006). Studies reporting the effi cacy of 
endovascular therapy are characterized by heterogeneous defi nitions of 
success (Diehm et al. 2007). Technical success, freedom from target lesion 
revascularisation and freedom from restenosis are commonly used endpoints 
in endovascular studies in stead of the traditional primary, assisted primary 
and secondary patency, which renders direct comparison with bypass surgery 
diffi cult.
Although PTA is a mini-invasive procedure which can be performed under 
local anesthesia, an early death rate of 2-3% in a recent series indicate that 
infrainguinal PTA is not without risk in the multimorbid patient group with 
CLI (BASIL trial participants 2005, Haider et al. 2006, Conrad et al. 2009).
Despite recent developments there are still patients with extensive 
infrainguinal disease and critical ischaemia beyond the endovascular therapy 
options (Norgren et al. 2007). Adequate treatment of the disease in the common 
femoral artery of in patients with CLI is important for the long-term fate of 
the leg and still requires open surgery in most cases (Lawrence and Chandra 
2010)
Major amputation
Major amputation above the ankle in CLI is indicated if the patient is non-
ambulatory, has life-thretening infection, their rest pain cannot be controlled, 
or extensive necrosis has destroyed the patient’s foot (Norgren et al. 2007, 
Schanzer and Conte 2010). Vascular reconstruction does not provide these 
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patients with a useful limb, and primary amputation is therefore a better 
option. For some CLI patients with severe co-morbidities or very limited 
chance of successful revascularisation, a primary amputation may be the most 
appropriate treatment (Biancari et al. 2000).
Spinal cord stimulation
Spinal cord stimulation has been proposed as an alternative treatment 
for patients with inoperable CLI. It is based on electrical stimulation of 
the spinal cord via an electrode that is positioned in the lumbal epidural 
space and connected to a subcutaneously implanted pulse generator. The 
stimulation generates paraesthesia in the ischaemic area of the leg and is 
believed to improve local microcirculation in the skin (Jacobs et al. 1990). 
This technique has been used very sparsely. A recent meta-analysis of six 
small trials including patients with unreconstructable CLI, showed a modest 
positive effect of spinal cord stimulation in terms of an 11% reduction in major 
amputation rates after 12 months compared with optimal medical therapy 
in patients with ischaemic rest pain or ulcer smaller than 3 cm in diameter 
(Ubbink and Vermeulen 2006). The authors concluded that the benefi ts of 
spinal cord stimulation should be weighed against the possible complications 
from this therapy. 
Pharmacotherapy 
Several pharmacological agents have been tried as an alternative to amputation 
in patients presenting with CLI who are unsuitable for reconstructive 
intervention. Prostanoids prevent platelet and leucocyte activation and protect 
the endothelium. A meta-analysis of randomised, controlled intravenous 
iloprost versus placebo trials showed that iloprost is effective with regard to 
decreased rest pain, ulcer healing and major amputation rates in short-term 
follow-up (Ruffolo et al. 2010). A reduction in ulcer size and presence of 
granulation tissue were considered as ulcer healing. The prediction of response 
is diffi cult and prostanoids are therefore rarely used (Norgren et al. 2007). 
Furthermore, there is no evidence for the long-term effectiveness and safety 
of prostanoids in patients with CLI (The i.c.a.i Study Group 1999, Ruffolo et 
al. 2010).
Biological treatment
Based on an increased mechanistic understanding of angiogenesis, novel 
therapeutic approaches including molecular, genetic and cell-based treatments 
are under way (Sneider et al. 2009). However, many questions remain to be 
answered, including the optimal delivery route, dosing, long-term outcome 
and safety.
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ANTITHROMBOTIC THERAPY
Antithrombotic therapy has proven benefi cial in preventing bypass graft 
occlusions (Dörffl er-Melly et al. 2003). Oral antiocoagulants have been shown 
to be more effective than acetylsalicylic acid (ASA) in preventing venous 
graft occlusion, while ASA has been more effective for prosthetic grafts 
(Dutch Bypass Oral anticoagulants or Aspirin Study Group 2000). As oral 
anticoagulation was associated with more bleeding in the Dutch study, ASA 
therapy is preferred over oral anticoagulants in many centres (Van Hattum 
et al. 2011). According to CASPAR study, patients with prosthetic grafts 
conferred benefi t of a combination of the two antiplatelet agents, ASA and 
clopidogrel, as compared to ASA alone (Belsch et al. 2010). This result was 
achieved when analysing the combined endpoint which was graft occlusion, 
graft intervention, major amputation or death. 
In addition to graft occlusion, CLI patients have an increased risk for 
myocardial infaction and stroke. The benefi t of antiplatelet therapy for 
secondary prevention of myocardial infarction and stroke in patients with 
cardiovascular disease has been evaluated and recommendations made for 
its use (Antitrombotic Trialists’ Collaboration 2002). The TASC II document 
recommends that antiplatelet therapy should be started preoperatively and 
continued after the leg revascularisation procedure indefi nitely and unless 
contraindicated (Norgren et al. 2007). 
Other components in the treatment of CLI 
Other components of treatment of the patients with ischaemic tissue loss 
include medical interventions to control pain in the ischaemic leg, local wound 
care, interventions to control infection and prevention of the progression of 
systemic atherosclerosis including blood pressure, glucose and lipid control. 
GRAFT SURVEILLANCE 
There is no consensus regarding the optimal graft surveillance program. The 
non-tolerance of vein grafts to thrombosis and the success of assisted patency 
support the recommendations that all infrainguinal venous bypass grafts should 
be followed by a regular regime of duplex scanning (Lundell et al. 1995, 
Landry et al. 2000, Visser et al. 2001, Armstrong et al. 2004). The purpose of 
the surveillance is to identify lesions that predispose to graft thrombosis and 
to allow their repair prior to graft occlusion. This recommendation has been 
questioned by a randomised European multicentre trial (Davies et al. 2005) and 
by two Finnish single centre randomised studies (Ihlberg et al. 1998, Ihlberg 
et al. 1999). These studies indicate that duplex surveillance of infrainguinal 
bypass grafts has no clinical benefi t in terms of graft patency or leg salvage. 
The newest TASC document recommends a clinical surveillance program, 
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including an interview for new ischaemic symptoms, pulse palpations and 
ABI measurements in the immediate postoperative period and every 6 months 
for at least two years (Norgren et al. 2007). As the occlusion of prosthesis is 
more unpredictable, a regular surveillance program of prosthetic grafts is not 
generally recommended (Lundell et al. 1995).
GRAFT OCCLUSION
Classically graft occlusion has been divided into three temporally distinct 
phases; early (less than 30 days after bypass surgery), intermediate (30 days 
to 2 years), and late (2 or more years) (Monahan and Owens 2009). Early 
occlusions are generally regarded as technical failures. Reasons for early graft 
occlusions include poorly constructed anastomosis, poorly selected infl ow 
or outfl ow sites, retained valve leafl ets, twisting or kinking of the graft, a 
poor-quality conduit and soft tissue infection (Donaldson 1992, Albäck and 
Lepäntalo 1998). Hypercoagulable states and hypotension also contribute to 
early graft failure (Monahan and Owens 2009). Intermediate graft occlusion is 
attributed to the formation of intimal hyperplasia. After 2 years, graft occlusion 
is commonly caused by the progression of atherosclerosis in the native infl ow 
or outfl ow arteries. Old vein grafts may degenerate and occlude.
Early occlusion affects 5% to 20% of infrainguinal bypass grafts (Shah et 
al. 1995, Albäck and Lepäntalo 1998, Conte et al. 2006) whereas intermediate 
to late graft occlusion has been reported to occur in 20% to 40% of cases 
within 5 years of surgery (Shah et al. 1995, Belkin et al. 1996, Pomposelli et 
al. 2003, Albers et al. 2006). Only 10 to 25% of patients are able to tolerate the 
occlusion of a limb salvage bypass and function effi ciently despite that (Veith 
et al. 2005). For most patients, the original symptoms will reappear. The 
severity of the ischaemia may even become worse due to reduced collateral 
fl ow caused by the division of vessels during surgery, physiological reduction 
of collateral fl ow during successful graft function and thrombosis extending 
into the outfl ow vessels (Henke et al. 2003, Veith et al. 2005). 
The approach to the individual patient with graft occlusion will vary based 
on a variety of criteria, including the overall condition of the patient, symptoms, 
the interval from bypass surgery, aetiology of graft occlusion, anatomy, and 
the availability of autogenous vein (Belkin 2009). Patients with tissue loss fare 
particularly poorly if the infrainguinal bypass graft permanently occludes. In 
the study by Baldwin et al. (2004), the 2-year leg salvage rate after graft failure 
was 34% for patients with tissue loss and 55% for those with rest pain. 
The aim of treatment in acute graft occlusion is to restore the patency of 
the original graft. The timing of the graft occlusion offers a clue to aetiology 
and the management strategy required. The procedures include removal of 
the thrombus either by thrombolysis or thrombectomy and identifi cation 
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and treatment of the aetiology of the thrombosis (Robinson et al. 1997, 
Belkin 2009). Graft correction procedures include distal extension grafts, 
interposition grafts, patch angioplasties and PTA. In a vein graft, thrombosis 
may cause widespread injury to the endothelium, and under these circumstanses 
consideration may be given to replace the whole graft instead of the removal 
of the thrombus since reported subsequent patency rates are poor (Belkin et al. 
1990, Robinson et al. 1997, Veith et al. 2005). 
REDO INFRAINGUINAL BYPASS SURGERY 
A redo infrainguinal bypass operation with a new graft can be challenging 
in patients with failed grafts beacause in most cases patients with limb-
threatening ischaemia tolerate multiple operations poorly (Rossi et al. 
2003). Patients with failed infrainguinal grafts seldom have opportunities for 
endovascular treatment due to long arterial occlusions (Belkin 2002). Although 
an endovascular procedure may have initially been succesful, the long-term 
patency is low in these patients and there is a need for repeat PTA and bypass 
procedures (Simosa et al. 2009). Scarring of the operative fi eld, lack of vein 
and severe atherosclerosis may present technical challenges to the surgeon. On 
the basis of these factors, it is not surprising that series examining the results 
of redo bypass surgery have shown inferior patency rates and leg salvage rates 
as compared to those achieved with the primary reconstruction (Belkin et al. 
1995, Henke et al. 2002, Pomposelli et al. 2003). Edwards et al. (1990) and 
Rossi et al. (2003) reported that after a redo bypass surgery, it is possible to 
achieve leg salvage rates similar to those after primary bypass surgery. Patient 
selection and inclusion of patients with claudication in addition to those with 
CLI may have contributed to the high leg salvage rates reported by Rossi et 
al. and Edwards et al.
Early primary graft failure, failed primary bypass performed with optimal 
autologous conduit and failed primary graft to an infrageniculate target artery 
have been reported to correlate with recurrent graft failure and a high major 
amputation rate (Rossi et al. 2003, Henke et al. 2002). 
HEALING PROCESS OF A WOUND
The healing of acute wounds has been described to occur by primary or 
secondary intention. This subdivision relates to healing after primary 
closure and healing in non-closed wounds. In principle, the healing process 
is similiar in both types: the only difference is the healing time (Gottrup 
2008). The healing process is divided into three histological based phases: 
infl ammation, proliferation and maturation. If parts of the dermis layer are 
intact, epidermal cells from skin appendages such as hair follicles quickly 
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cover the wound. If dermis is totally destroyed, the epithelialization only 
takes place from the wound edges. 
Chronic wounds have failed to progress through the normal stages of healing 
and enter a state of pathologic uncontrolled infl ammation, which causes further 
injury and impairs healing (Menke et al. 2007, Gottrup 2008). The mitogenic 
activity of cells in a chronic wound becomes suppressed (Menke at al. 2007). 
Non-healing ulcers are prone to complications like infection that not only 
affect the healing but also have a negative impact on the patients themselves.
It has long been recognized that the healing of ischaemic tissue lesions 
requires additional blood perfusion higher than that required for intact skin 
or tissue staying vital. The successful treatment of ischaemic tissue loss rests 
on the possibility of adequately increasing the perfusion to supply oxygen 
and nutritients. Several other factors are also involved in the healing of 
tissue defects (Medina et al. 2005, Gottrup 2008) (Table 3). Tobacco smoke 
contain several substances that are harmful for wound healing, such as carbon 
monoxide causing hypoxia and nicotine leading to vasoconstriction as well as 
diminishing cell proliferation. Uremic patients have impaired wound healing 
due to calcifi ed arteries, anemia, malnutrition and impaired immunity.
Table 3. Factors infl uencing the healing of wounds 












congenital disorders (epidermolysis bullosa, Marfan) 
connective tissue diseases
medications (chemotherapeutic drugs, glucocorticoid steroids)
malignancy
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Despite the revascularisation of large arteries, peripheral tissue hypo-
perfusion occur. The microcirculatory pathophysiology is not completely 
understood. The low tissue perfusion pressure in an ischaemic leg may cause 
changes in the arterioles and in the microcirculation, including morfological 
alterations and endothelial dysfunction (Coats and Wadsworth 2005). The 
revascularisation procedure generates a sudden increase of blood pressure 
in the weakened microvasculature, which may lead to extravasation of fl uid 
and tissue oedema. Oedema formation can compress capillaries and impair 
diffusion of nutritients to the surrounding tissue. The impaired microcirculation 
and oedema may cause failure of improvement after revascularisation despite 
a patent graft.
BACTERIA IN A CHRONIC WOUND
Ischaemic tissue lesions are open for a prolonged period of time and tend to 
become colonised by bacteria. Devitalised tissue serves as a rich environment 
for bacterial growth (Steed et al. 2006). Necrotic tissue is laden with bacteria 
(Hopf et al. 2006). Staphylococcus aureus is the most commonly identifi ed 
pathogen, up to 88%, in a chronic wound (Finnish Current Care Guideline 
for chronic leg ulcers 2007). Other common bacteria include Enterococcus, 
Pseudomonas, Enterobacter and beta-hemolytic Streptococcus. Anaerobic 
bacteria may also be found in chronic wounds. Generally, more than one 
bacterium is identifi ed in chronic wounds. The relationship between bacterial 
colonization and wound healing is unclear (Hopf et al. 2006). Routine use of 
antimicrobial therapy should be avoided due to the development of resistance. 
Clinical signs of infection include erythema, warmth, oedema, lymphangiitis 
and pain around the wound and the presence of purulence (Lavery et al. 1996). 
If there is suspicion of infection, bacterial specimens should be taken from the 
wound. The antimicrobial therapy should be based on the culture result and 
susceptibility data. If culture results are unavailable, the antimicrobial therapy 
ought to aim at the most important pathogens Staphylococcus aureus and beta-
hemolytic Streptococcus (Steed et al. 2006, Finnish Current Care Guideline for 
chronic leg ulcers 2007). Systemic signs of infection, osteomyelitis and local 
cellulitis should be treated with systemic antimicrobial therapy whereas mild 
infections can be treated with oral antimicrobial therapy. There are scarce data 
regarding the choice or length of antimicrobial therapy. Guidelines recommend 
that antimicrobial therapy should be continued until there is evidence that the 
acute infection has resolved, but not necessarily until the wound has healed 
(Finnish Current Care Guideline for chronic leg ulcers 2007). In case of 
infection, adequate mechanical debridement of devitalised and infected tissue 
is important (Hopf et al. 2006, Finnish Current Care Guideline for chronic leg 
ulcers 2007).
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LOCAL WOUND CARE AND SURGERY
The aim of the wound bed preparation of a chronic tissue lesion is to convert 
the molecular and cellular environment to resemble more that of an acute 
wound in order to accelerate endogenous healing or facilitate the effectiveness 
of other therapeutic measures (Hopf et al. 2006). Debridement is required to 
remove the obviously necrotic tissue, excessive bacterial burden and cellular 
burden of dead and senescent cells with the aim of leaving clean, viable tissue. 
Debridement may be undertaken mechanically, surgically (sharp debridement), 
biologically (larvae), biochemically (enzymatic) or chemically (antiseptics) 
(Hopf et al. 2006, Hinchliffe et al. 2008). More than one debridement method 
may be appropriate. Although sharp surgical debridement is preferred, the 
method chosen may depend on the status of the wound, the overall condition 
of the patient and the capability of the health care provider (Hopf et al. 2006, 
Finnish Current Care Guideline for chronic leg ulcers 2007). 
It has been recognised that wound healing is optimal when the wound is 
kept in a moist environment, which favors cell migration and matrix formation. 
Saline gauze is the tradional wound dressing. Dressings have been developed to 
promote wound healing, reduce pain and absorb blood as well as tissue fl uids. 
Modern dressings include hydrocolloid dressings, alginates, foam dressings, 
hydrofi ber dressings, activated charcoal dressings, silver-coated dressings, 
dressings containing hyaluron acid or protease-modulating matrix. The choice 
of the ideal dressing remains controversial. There is no evidence that any 
of the modern dressings is better than the other, or better than saline gauze 
(Chaby et al. 2007). Other methods used to promote healing of the tissue lesion 
include negative pressure wound therapy, hyperbaric oxygen and bioactive 
local therapy products, including growth factors as well as electrical, magnetic, 
ultrasound and laser therapies. More research is needed to evaluate the most 
effective method to speed up the healing process (Hopf et al. 2006, Finnish 
Current Care Guideline Working Group for chronic leg ulcers 2007). The tissue 
defect should be offl oaded if there is an increase in pressure (Steed et al. 2006). 
Surgical debridement of dry, non-infected gangrenous lesions should not be 
performed before vascular evaluation or revascularisation (Hopf et al. 2006, 
Finnish Current Care Guideline Working Group for chronic leg ulcers 2007). 
Gangrenous tissue, if not infected, can form an echar, shrink and eventually 
mummify and allow subsequent spontaneous amputation to follow (Norgren at 
al. 2007). The most important step in the control of a deep infection is urgent 
incision, drainage of an abscess and a radical debridement of all infected, 
non-viable necrotic tissue (Vuorisalo et al. 2009, Pendsay 2010). In case of 
infection, skin should be always left open. Osteomyelitis is most effectively 
treated by removing the infected bone (Hopf et al. 2006, Steed et al. 2006). 
Local anesthesia of feet with poor circulation or infection should be avoided 
(Vuorisalo et al. 2009). When healing by second intention is not considered, the 
wound may be closed or covered in a number of ways (Figure 5). 
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Figure 5. Reconstructive ladder for treatment of acute wounds: the aim is to convert 
a chronic ulcer to an acute healing wound. The selection of appropriate level is of 
importance. Modifi ed from Janis et al. (2011).
CLASSIFICATION OF TISSUE DEFECTS IN THE LEG
Dozens of different classifi cation systems have been developed to categorise 
foot ulcers (Schaper et al. 2004). A classifi cation which is easy to use and which 
provides a description of tissue defect will help in planning treatment strategies 
and predicting outcomes in terms of ulcer healing and major amputation, while 
also facilitating communication between health-care providers. Shea, in 1975, 
was one of the fi rst to propose a standard wound classifi cation system (Shea 
1975). His scheme was designed to assess decubitus ulcerations and was mainly 
based on ulcer depth. One of the most commonly cited ulcer classifi cation 
systems was fi rst described by Meggit in 1976 and popularized by Wagner in 
the next decade (Wagner 1981). The Wagner classifi cation is based on wound 
depth and consists of six grades (Table 4). The Wagner classifi cation does not 
take ischaemia into account. The University of Texas Wound Classifi cation 
System (UTWCS) evaluates the depth of the ulcer, the presence of infection 
and ischaemia as well (Lavery et al. 1996) (Table 5). The UTWCS system has 
been prospectively evaluated in diabetics, showing that the risk of amputation 
increases with increasing grade and stage of the foot lesions (Armstrong et al. 
1998, Oyibo et al. 2001). Diabetic patients with infection and ischaemia were 
nearly 90 times more likely to receive a midfoot or higher lever amputation 
compared with patients in less advanced wound stages (Armstrong et al. 1998). 
If the lesion penetrated to bone, the patient was 11 times more likely to receive 
a midfoot or higher level amputation. Oyibo et al. reported a stepwise increase 
in the healing time of the tissue defect with each stage of the UTWCS in 
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patients with diabetes. The UTWCS predicted healing time better and showed 
a greater association with increased risk for amputation when compared with 
the Wagner classifi cation system (Oyibo et al. 2001). The PEDIS classifi cation 
is a newer one (Schaper 2004). The PEDIS classifi cation system is developed 
for research purposes and is more complex. It is designated especially for the 
diabetic foot and classifi es foot ulcers within fi ve categories: perfusion (P), 
extent (E), depth (D), infection (I), and sensation (S). 
Table 4. Wagner classifi cation of foot ulcers (Wagner 1981).
Grade Description of the ulcer
0 Pre- or post-ulcerative lesion completely epithelialized
1 Superfi cial, full-thickness ulcer limited to the dermis, not extending to the 
subcutis
2 Ulcers of the skin extending through the subcutis with exposed tendon or 
bone without osteomyelitis or abscess formation
3 Deep ulcers with osteomyelitis or abscess formation
4 Localised gangrene of the toes or forefoot
5 Foot with extensive gangrene
OUTCOME MEASURES AFTER IBS
In 1997, the Ad Hoc Committee published a revised version of recommended 
reporting standards for patients who present with lower-extremity ischaemia 
(Rutherford et al. 1997). The cornerstones of success after vascular intervention 
were leg salvage and patency. The Trans-Atlantic Conference on Clinical Trial 
Guidelines in PAD recommended the following primary endpoints for reporting 
the results of treatment in CLI; complete relief of rest pain for Fontaine stage 
III, complete ulcer healing for both legs for Fontaine IV and major amputation 
rates (Labs et al. 1999). A composite endpoint including amputation and death 
or amputation, death and morbidity and was considered superior to mortality 
alone. Recently, patient-oriented outcomes, such as health-related quality of 
life and functional outcome, have been appreciated (Engelhardt et al. 2008, 
Taylor et al. 2009). However, no quality-of-life questionnaire has been 
standardised in evaluating patients with CLI (Landry 2007, Varu et al. 2010). 
This may be because patients often are clinically unstable and the treatments 
offered in CLI involve signifi cant morbidity (Varu et al. 2010). A recent PAD 
consensus meeting considered amputation-free survival the most important 
end-point of treatment for CLI (Norgren et al. 2010). 
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Infection: Presence of frank purulence and/or two or more local signs of infection (warmth, 
erythema, lymphangiitis, lymphadenopathy, oedema, pain, loss of function). The diagnosis 
of infection may also be assisted by laboratory studies or positive deep cultures from the 
lesion.
Ischaemia: One additional clinical sign (claudication, rest pain, pallor on elevation, absence of 
pedal hair, absence of pedal pulses) coupled with one or more non-invasive measurements 
(ABI < 0.80, TP < 45mmHg, TcpO2 < 40 mmHg).
Table 5. The University of Texas Wound Classifi cation System (Lavery et al. 1996).
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Ulcer healing time 
Ulcer healing time is rarely used as endpoint after revascularisation for CLI 
although it is recommended as a parameter for reporting the success of treatment 
for CLI (Labs et al. 1999). Hoffman et al. (2007) did a computerised literature 
research (1985-2005) and identifi ed 1915 articles on revascularisation in CLI. 
Information about ulcer healing time was reported only in 6 studies after 
surgical revascularisation and in 11 studies after endovascular or combined 
endovascular and surgical revascularisation. 
The time required for healing of ischaemic tissue defects predominantly 
accounts for the delay in the healing time (Chung et al. 2006). The incisional 
wounds require less time to heal. Chung et al. analysed 159 patients with rest 
pain and 250 patients with tissue loss treated with IBS. Median healing time 
was 75 days for the incisional wounds and 198 days for the ischaemic tissue 
defects. At 6 months 48% of the ischaemic tissue defects had healed, and at 12 
months 76%. The corresponding healing rates for the incisional wounds were 
79% and 93%.
Berceli et al. (1999) reviewed 432 pedal bypass grafts placed for ischaemic 
tissue loss in the forefoot or heel. The median ulcer healing time was 139 
days. Healing rates for forefoot and heel lesions were similar. The authors 
commented that the heel lesions might have been superfi cial as only a minority 
required local ulcer surgry. It is worth noting that 79 patients were excluded 
from the study by Berceli et al. because the healing of the lesions could not be 
followed up for more than 3 months or the location of the lesion could not be 
determined retrospectively.
Wölfl e et al. (2003) compared ulcer healing time in patients with and 
without diabetes in a retrospective study. Gangrenous lesions could be slightly 
better remedied in diabetics compared to non-diabetics (at 1 year 94% vs. 
87%). With regard to healing of ischaemic ulcers, a trend against diabetics 
was noted with a healing rate of 81% compared to 96% at one year after IBS. 
The fact that Wölfl e and colleagues only included patients with a patent graft 
throughout the whole fi rst postoperative year in their series may explain the 
high healing rates.
The proportions of ischaemic tissue defects that completely healed were 
reported to be similar after IBS to inframalleolar arteries and distal fi bular 
artery in a study by Ballotta et al. (2008). The avarage time to ulcer healing 
was 20 weeks in the inframalleolar artery group compared to 23 weeks in the 
fi bular artery group. 
Ballotta et al. (2010) analysed the complete ulcer healing time in 164 
patients over 80 years old with a life-expanctancy over one year. The mean 
time to complete healing for all wounds, incisional and ischaemic, after 
infrapopliteal bypass surgery was 21 weeks.
Goshima et al. (2004) analysed retrospectively 174 patients undergoing 
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IBS for ischaemic tissue loss. Of those 137 patients who were available for 
follow-up, 46% had achieved complete ulcer healing at 3 months after the 
bypass surgery.
The series by Nicoloff et al. (1998) included 74 patients undergoing IBS for 
ischaemic tissue loss. The median ulcer healing time was 3.4 months (range 
from 0.4 to 48 months).
A Brazilian series described 11 patients undergoing infrainguinal bypass 
grafting to perigeniculate collaterals, which had developed due to popliteal 
artery occlusion (Brochado-Neto et al. 2000). Median follow-up was 19 months 
(range from 6 to 43 months). The bypasses contributed to successful healing of 
the ischaemic tissue defect in 7 patients (64%) during the follow-up. 
Some authors have analysed ulcer healing time without differentiating the results 
from different treatment modalities. Treiman et al. (2000) reviewed 91 patients 
with ischaemic tissue loss in the heel. 81 (89%) were treated with IBS, 4 had 
suprainguinal revascularisation, 3 had infrainguinal PTA and 3 major amputation. 
The ulcer healing rate was 73% at 6 months for the whole study group. The study 
by Konradsen et al. (1996) included 42 legs with ischaemic tissue defects. IBS was 
performed to 67% (28 legs) whereas the other legs were treated endovascularly or 
had suprainguinal bypass surgery. The ulcer healing rate was 70% at 12 months. 
Patients undergoing IBS were not analysed separately. The study by McCulloch et 
al. (2003) included 93 cases with uncomplicated leg ulcers. Only 35% had some 
kind of surgical or endovascular revascularisation. The ulcer healing rate was 51% 
at 12 months for the whole study group. McCulloch and colleagues concluded 
that patients with extensive ulcers or ulcers that do not improve with conservative 
treatment should be considered for revascularisation.
Patency
Patency is a direct measure of revascularisation success when bypassing or 
reopening occlusions. There are less data concerning graft patency than for 
leg salvage and survival. Verifying the status of the graft requires a vascular 
investigation. The Ad Hoc Committee has proposed criteria for graft patency 
(Rutherford et al. 1997). Primary, assisted primary and secondary graft patency 
rates are traditional means for assessing the outcome after IBS but knowledge 
regarding tertiary patency rates is scarce (De Luccia et al. 2008) (Table 6). 
While primary, assisted primary and secondary patency evaluate the patency 
of one graft, tertiary patency also takes redo bypasses into account, thereby 
describing the whole period of time with a patent infrainguinal bypass graft in 
a leg (Rutherford et a. 1997). De Luccia and colleagues analysed the outcome 
after above-knee femoropopliteal bypasses in a patient group (53 limbs) where 
the vast majority, 94%, had tissue loss as indication. The 3-year primary, 
secondary and tertiary patency rates were 76%, 78% and 90% respectively. 
A meta-analysis of 29 trials including 12,320 reconstructions with vein 
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grafts to the infrapopliteal arteries reported at 1-month a pooled estimate of 
93% for primary patency and 95% for secondary patency (Albers et al. 2006). 
The monthly failure rate decreased progressively to less than 1% at 8 months 
and remained below this level thereafter. The pooled estimate at 5 years for 
primary patency was 63% and for secondary patency 71%. The great majority 
of the patients, 88%, had ischaemic tissue loss but that patient group was not 
analysed separately.
The status of the outfl ow vessels is an important determinant of graft 
performance (Biancari et al. 1999, Seeger et al. 1999). Lack of suitable 
outfl ow vessel makes revascularisation impossible. The evaluation of the run-
off vessels is not always simple (Conte 2009) as it is based of the quality of 
angiograms. Other important predictive factors of bypass graft outcome are 
conduit selection and technical factors. Albäck and Lepäntalo (1998) studied 
immediate failure of vein grafts and found that almost half of the occlusions 
were graft related. Other causes were poor run-off and technical reasons. 
Few studies have analysed how the indication for leg salvage surgery affects 
infrainguinal graft patency. Nasr and colleagues (2003) reported lower primary, 
assisted primary and secondary graft patency rates in patients presenting with 
gangrene (at 5 years: 33%, 46% and 48%) compared to patients presenting 
with ischaemic ulcers (52%, 70% and 76%) and rest pain (51%, 72% and 
75%). 
Leg salvage
Leg salvage or foot preservation is easy to retrieve and a favoured endpoint 
of CLI studies (Table 6). Leg salvage is an indirect measure of the success of 
revascularisation since there are factors besides revascularisation affecting the 
outcome. The key question is what the leg outcome would be if untreated or 
treated only conservatively. Several studies have shown an inverse correlation 
between the incidence of infrainguinal bypass reconstruction and major 
amputation (Holstein et al. 2000, Luther et al. 2000, Eskelinen et al. 2003).
The meta-analysis of 29 popliteal-to-distal bypass trials by Albers et al. 
(2006) reported high long-term leg salvage rates and emhpasised the durability 
of bypass surgery with vein graft in the treatment of CLI. The pooled estimate 
of leg salvage was 89% at 1 year and 78% at 5 years. 
The infl uence of the mode of CLI-presentation on leg salvage rates has 
been studies by Luther and Lepäntalo (1997) and Nasr et al. (2003). Luther 
and Lepäntalo reported higher amputation rates both in short and longterm 
follow-up for patients with gangrene compared to patients with ulcer and rest 
pain as indication for femorotibial bypass surgery. The leg salvage rates for 
patients with gangrene, ulcer and rest pain were at 3-month 74%, 85% and 
93% and at 5 years 57%, 72% and 72%, respectively. In the study by Nasr 
and colleagues the leg salvage was 59% at 5 years for patients presented with 
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gangrene compared to 87% for patients with ischaemic ulcers and 83% for 
those with rest pain. 
Patency-leg salvage gap
Patency-leg salvage gap is the difference between leg salvage rate and 
patency rate after revascularisation. The gap describes the proportion of leg 
preservation not attributable to verifi ed graft patency of the treated arterial 
segment. Interestingly, in addition to many endovascular series, bypass series 
have also reported high leg salvage regardless of the secondary patency rates 
(DeRubertis et al. 2007, Eskelinen and Lepäntalo 2007). Suggested reasons for 
the gap include the performance of additional revascularisation procedures, the 
improvement of collaterals and adequate perfusion provided by early patency 
to heal the ischaemic lesions which do not recur with graft occlusion (Veith 
2005, Romiti et al. 2008). 
Survival
Survival, like leg salvage, is relatively easy to retrieve and a favoured outcome 
of CLI studies. Early postoperative (30-day) mortality after IBS for CLI has 
ranged from 1 to 5% in large series (Zdanowski et al. 1998, Pomposelli et al. 
2003, Conte et al. 2006, Biancari et al. 2007). Long-term survival after IBS has 
been low in the reports published (Table 6). In the study by Pomposelli et al. 
(2003) the 5- and 10-year survival was 49% and 24% for patients undergoing 
pedal bypass grafting. CLI-patients typically have a number of comorbidities. 
These often determine the fate of the patient regardless of the fate of the bypass 
graft. Multiple risk factors have been identifi ed as important contributors to 
the increased mortality, including advanced age at CLI-presentation, diabetes, 
coronary artery disease, continued tobacco use, and dialysis dependence 
(Lassila et al. 1986, Lassila and Lepäntalo 1988, Biancari et al. 2000, Nehler 
et al. 2003).
The presence of ischaemic tissue loss has been reported to increase the 
mortality risk by a factor of 2.7 as compared to rest pain for patients undergoing 
femorotibial bypass surgery (Luther and Lepäntalo 1997). In the study by 
Luther and Lepäntalo, 5-year survival was the lowest among patients with 
gangrene (31%), whereas patients with ulcer and rest pain achieved better 
survival rates, 56% and 72%, respectively. 
Amputation-free survival 
The series by Seeger et al. (1999) is one of the few studies analysing 
amputation-free survival for patients with ischaemic tissue loss (Table 6). 
At discharge from hospital after IBS, 85% of the patients were alive without 
major amputation, and at 6 months, the rate was 81%. The decrease in the AFS 
was mainly due to the mortality.
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Schanzer et al. (2008) developed a scoring system for predicting AFS 
in patients with CLI. Using the PREVENT III cohort (Conte et al. 2006) 
Schanzer and colleagues identifi ed fi ve independent predictors of AFS after 
IBS. Tissue loss was the second most important predictor for loss of limb or 
life. The predictors and their risk scores were: dialysis-dependent renal failure, 
4 points; tissue loss, 3 points; age ≥75 years, 2 points; a hematocrit <30%, 2 
points; and a history of advanced coronary artery disease, 1 point. The model 
predicted that the one year amputation-free survival was 86% for patients with 
≤ 3 points (low risk), 73% for patients with 4 to 7 points (medium risk), and 
45% for patients with ≥8 points when undergoing IBS with vein. Similarly, 
Biancari et al. (2007) using data from the Finnish vascular registry (Finnvasc) 
found four independent predictors for AFS after leg salvage surgery, one of 
those being the presence of gangrene at presentation. The other risk factors 
were diabetes, coronary artery disease and urgent operation.
STUDIES COMPARING IBS WITH PTA
There are few randomised controlled studies available that compare IBS with 
PTA. Most of them include a majority of claudicants, and none of them give 
proper information on tissue loss. The British Angioplasty versus Surgery in 
Ischaemic Legs Trial (BASIL) is the only large trial that compares bypass 
surgery and PTA in a randomised fashion (BASIL Trial participants 2005). 
The trial included patients that were clinically considered candidates for 
either infrainguinal PTA or bypass for severe limb ischaemia. Seventy-four 
percent of the patients presented with tissue loss. IBS was associated with 
signifi cantly lower immediate failure (3% vs. 20%), higher 30-day morbidity 
(57% vs. 41%), and lower 12-month reintervention (18% vs. 26%) rates than 
PTA. The 30-day mortality was similar, 5% in the bypass group and 3% in the 
PTA group. AFS at 1 and 3 years was not signifi cantly different; 68% and 57% 
for the bypass group and 71% and 52% for the PTA group. However, a post-
hoc analysis demonstrated that for those patients who survived for 2 years 
after randomisation, initial randomisation to bypass surgery was associated 
with a signifi cant increase in subsequent survival of about 7 months and an 
increase in subsequent AFS of about 6 months (Bradbury et al. 2010). The 
BASIL trial recommended that patients who are expected to live for more 
than 2 years after revascularisation should be considered for bypass surgery if 
good vein is available because bypass is more durable than PTA. No patency 
data were available in the BASIL trial. The generalisability from the BASIL 
trial was audited from a sample of 456 patients with infrainguinal disease. 
236 of the patients underwent revascularisation during the recruitment period 
and 29% of them were regarded suitable for randomisation, i.e. treatment by 
either method. This fi nding illustrates the narrow overlap of the indications 
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for bypass and PTA and does not well represent the whole group of patients 
with infrainguinal lesions. The same holds true with Scandinavian Thrupass 
versus Bypass Study, where occlusions of the superior femoral artery were 
randomised between endografts and bypasses with prosthesis (Lepäntalo et al. 
2009). Four percent of the femoral artery occlusions fi tted in the tight inclusion 
criteria, which were chosen to exclude short occlusions and lesions with an 
unfavourable landing zone for endografts. The patency difference was in 
favour of surgical bypass over endovascular thrupass both in the Scandinavian 
Thrupass versus Bypass trial and the trial by van der Zaag and colleagues 
(2004) when treating superfi cial femoral artery occlusions. The vast majority 
of the patients included in these two trials were claudicants, and patients with 
CLI were a minority. One randomised trial has reported simliar patency for 
bypass and thrupass in the treatment of occlusive lesions in the superfi cial 
femoral artery (McQuade et al. 2010). Even in the study by McQuade and 
colleagus, the majority had claudication as treatment indication.
PRESENCE OF MULTIDRUG RESISTANT BACTERIA 
AS A SPECIFIC COMORBIDITY
Multi-drug resistant Pseudomonas aeruginosa (MDR Pa)
Patients hospitalised for a long time are frequently colonized by Pseudomonas 
aeruginosa (P. aeruginosa) bacterium (Agodi et al. 2007). P. aeruginosa is one 
of the leading causes of nosocomial infections (Aloush et al. 2005 Agodi et 
al. 2007). P. aeruginosa has an ability to develop resistance against almost all 
antimicrobial agents and many disinfectants (Hanock 1998, Hoquet et al 2007). 
There is no clear international consensus regarding the defi nition of multidrug 
resistance in P. aeruginosa. MDR Pa is usually defi ned as resistance to three 
or more of the following antimicrobial agents: antipseudomonal penicillins 
(e.g. piperacillin), antipseudomonal cephalosporins (e.g. ceftazidime), 
fl uoroquinolones (e.g. ciprofl oxacin), carbapenems (e.g. imipenem, 
meropenem), and aminoglycosides (e.g. gentamycin, tobramycin, amikacin) 
(Giske et al. 2008). A European study of nosocomial infections showed a 
prevalence of 5% of multidrug resistance in P. aeruginosa (Gales et al. 2001). 
In individual institutions, the rates of multidrug resistance in P. aeruginosa 
are even higher than those reported in large surveillance studies (Goossens 
et al. 2003, Obritisch et al. 2005). Patients with MDR Pa infections should 
be treated with synergistic antimicrobial agents and the underlying disease 
should be attacked (Obritsch et al. 2005, Hoquet et al. 2007).
P. aeruginosa is an opportunistic pathogen. It is responsible for a wide range 
of infections: it can cause respiratory tract infections, ear and eye infections, 
soft tissue infections, urinary tract infections, gastrointestinal infections, bone 
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and joint infections and septicaemia (Brooks and Carroll 2004). P. aeruginosa 
is known to be a potentially particularly virulent pathogen, producing 
enzymes which can digest vascular tissue (Bandyk and Esses 1994). The 
bacterium prefers a moist environment, and it fi nds numerous reservoirs in 
the hospital: sinks, toilets, showers, taps, food, respiratory equipment, and 
even disinfectants. The presence of foreign bodies as prosthetic bypass grafts 
enhances the infectivity of P. aeruginosa and impairs eradication (Bandyk and 
Esses 1994).
The infl uence of MDR Pa on mortality
The clinical relevance of MDR Pa has been stressed in reports of nosocomial 
infections and outbreaks among critically ill patients and in intensive care 
units in several countries (Lyytikäinen et al. 2001, Cao et al. 2004, Kang et 
al. 2005, Aloush et al. 2006, Gasink et al. 2006). Several case-control studies 
have shown an association between MDR Pa and increased mortality (Cao et 
al. 2004, Kang et al. 2005, Aloush et al. 2006, Zavascki et al. 2006, Giske et 
al. 2008). The reported in-hospital mortality rate among patients with MDR 
Pa has varied between 21% and 83% (Kang et al. 2005, Aloush et al. 2006, 
Gasink et al. 2006, Zavascki et al. 2006). To the best of our knowledge, no 
published study has analysed the effects of MDR Pa in patients suffering from 
CLI.
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7. AIMS OF THE PRESENT STUDY
The main purpose of this study was to analyse the outcome after IBS in patients 
with CLI and tissue loss (Fontaine IV).
The specifi c aims were to:
1. Assess the complete ulcer healing time, including healing of the ischaemic 
tissue lesions and incisional wounds, and investigate factors affecting the 
complete ulcer healing time. Analyse local factors infl uencing the healing 
time of the ischaemic tissue lesions (I-II) 
2. Evaluate the long-term outcome after infrainguinal bypass surgery in 
patients with ischaemic tissue loss (III)
3. Analyse the results of redo infrainguinal bypass surgery (IV) 
4. Compare bypass surgery and endovascular transluminal angioplasty to the 
infrapopliteal arteries as fi rst-line revascularisation strategies in CLI (V)
5. Evaluate the consequences of a multi-drug resistant Pseudomonas 
aeruginosa-outbreak among CLI-patients undergoing infrainguinal bypass 
surgery (VI)
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Figure 6. A total of 1265 CLI patients (1038 patients with Fontaine IV + 227 patients 
with Fontaine III) in the diff erent study years (2000- 2007) and the number of patients 
included in each study (I-VI).
8. PATIENTS AND METHODS
PATIENTS
The present study included 1038 patients with ischaemic tissue loss (Fontaine 
IV) and 227 with ischaemic rest pain (Fontaine III) (Figure 6). All patients in 
this study underwent revascularisation for CLI at the Department of Vascular 
Surgery, Helsinki University Central Hospital (HUCH), which serves as 
the academic vascular surgical centre for a population of 1.5 million people 
in Southern Finland. The characteristics of the patients and procedures are 
presented in Tables 7 and 8.
Study I. A prospective cohort study was undertaken to analyse the 
complete ulcer healing time. One hundred fi fty consecutive legs treated with 
infrainguinal bypass grafting for CLI with ischaemic tissue loss (Fontaine 
IV) were recruited. Patients with redo IBS were excluded. The infrainguinal 
bypass operations were performed between January 2005 and July 2006. The 
follow-up period was one year.
Study II: In order to analyse the infl uence of local characteristics of the 
ischaemic tissue defect on the ulcer healing time, a prospective study was 
undertaken. All patients undergoing IBS in 2006 for CLI with tissue loss 
(Fontaine IV) were enrolled in the study. The study cohort consisted of 110 
patients with 113 critically ischaemic legs with tissue loss. The follow-up 
period was one year.
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   74 
(37-99) 
74 75      75 
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Renal function 
    s-cr: median (range) 
    eGFR: mean (range) 
    ESRD with dialysis 
    
     - 
     - 
    11 (7) 
    
     - 
    - 
   8 (7) 
    
     - 
61 (5-250) 
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       - 
 62 (5-169)  
     - 
 
    123 
      70 
       - 
 
143 
  62 
    - 
 
97 (40-626) 
        - 
        - 
 
96 (53-195) 
        - 





    0.43 
(0-2.30) 
   
 0.43 
(0-1.69) 
   
 0.24 
(0-2.70) 
   
      0.45 
(0.43-2.48) 
    
      -  
   
  - 
      
      0.41 
(0.26-2.70) 
     
     0.37 
(0.21-1.84) 
Coronary artery disease:  documented coronary artery disease, previous coronary bypass surgery, history of myocardial infarction or angina 
pectoris or  ischaemia on ECG. 
Cerebrovascular disease: history of stroke or transient ischaemic attack 
Chronic pulmonary disease: chronic obstructive pulmonary disease or asthma 
Diabetes mellitus: hyperglycemia requiring diet or medication 
Hypertension: medication for hypertension or blood pressure repeatedly > 160/90mmHg 
Hyperlipidemia: medication for hyperlipidemia or fS-cholesterol  >5 mmol/L or S- LDLcholesterol  >3 mmol/L  
BMI body mass index (kg/m2)   
s-cr: serum creatinine (μmol/l) 
eGFR: glomerular filtration rate (mL/min/1.73m 2) 
ESRD: end stage renal disease 
ABI: ankle-brachial index 
 
Table 7. demographics of the study groups (I-VI)
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No of legs included   150     113 636 651 761 262   64  64 
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- proximal popliteal artery (%) 
- distal popliteal artery (%) 
- tibioperoneal trunk 
- crural artery (%) 
- doral pedal artery (%) 
- plantar artery (%) 
 
   16 (11) 
   32 (21) 
     1 (1) 
 69 (46)   
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   3 (3) 
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23 (20)       
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    7  (1) 
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 47 (18) 
213 (81) 
    2 (1) 
    0 (0) 
 
    3 (5) 
14 (22) 





 3 (5) 
14 (22) 
  0  (0) 
47(73)*  
 
   
*) includes crural and pedal arteries 
Table 8. Surgical data (Studies I-VI).
Study III: A retrospective study was undertaken to evaluate the long-
term outcome in patients with CLI and tissue loss (Fontaine IV) undergoing 
infrainguinal bypass grafting. Data on all patients treated with unilateral IBS 
for ischaemic tissue loss between January 2000 and December 2006 were 
collected. This study included 636 patients. Follow-up ended in December 
2009 or at the patient’s time of death whichever occurred fi rst.
Study IV: In order to evaluate the need and results of redo infrainguinal 
bypass grafting data on all patients treated with primary IBS for ischaemic 
tissue loss (Fontaine IV) between January 2000 and December 2005 were 
collected. This retrospective study included 593 patients with 651 critically 
ischaemic legs with tissue loss. The follow-up terminated on June 2009 or at 
the patient’s time of death, whichever occurred fi rst. 
Study V. In order to compare the results of bypass surgery with PTA 
in patients with CLI, we retrospectively analysed the patients who had 
undergone a primary unilateral infrainguinal revascularisation extending to 
the infrapopliteal arteries between January 2000 and December 2007. This 
retrospective study comprised 761 patients treated with IBS and 262 patients 
treated endovascularly. As treatment groups may differ markedly with respect 
to the observed pretreatment covariates, a propensity score analysis was 
developed to control for all known patient factors that might be related to the 
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decision to perform either bypass surgery or PTA. The mean length of follow-
up was 2.4 years.
Study VI. An outbreak of multidrug-resistant Pseudomonas aeruginosa 
occurred in our vascular surgical ward in HUCH during a 13-month period. 
In April 2000, the fi rst MDR Pa culture was obtained from a patient. The P. 
aeruginosa strain was resistant to ciprofl oxacin, tobramycin, and a combination 
of piperacilline and tazobactam. 129 patients presented with MDR Pa until 
the source was eventually localized to a showerhead in March 2001. The 
case group comprised those 64 patients who had undergone IBS for CLI and 
were contaminated with MDR Pa during the outbreak. A control patient with 
negative MDR Pa culture was matched to each case patient according to 
sex, age (+/- 10 years), presence of diabetes, Fontaine class (III or IV), graft 
material (vein or prosthesis) and site of distal anastomosis ( proximal popliteal 
artery or distal popliteal artery or crural/pedal artery). Follow-up for this study 
terminated 5 years after IBS.
METHODS
Data collection
HUSVasc registry is the vascular registry of HUCH. The HUSVasc registry 
data include demographic data on the patients, indication for revascularisation, 
the preoperative UTWCS class of the ischaemic tissue lesion, specifi c 
revascularisation details, specifi c details of vascular reintervention, type 
of local ulcer surgery, information on patency as well as the date of ulcer 
healing, major amputation and death. Data related to the patients in the studies 
I and II were prospectively added into the HUSVasc registry at variable time 
points within the course of each patients care. Data related to the patients in 
the retrospective studies III-V were collected from the HUSVasc registry. In 
study VI, the HUSVasc data of patients treated with IBS between January 
2000 and June 2003 were scrutinised to identify controls for the MDR Pa 
positive cases. HUSVasc registry data of all patients included in this study (I-
VI) were manually cross-checked with the patients’ records, and missing data 
was retrieved from the patients’ records. Amputation status was completed 
from fi les of the National Institute of Health and Welfare (III-VI). Survival 
data were confi rmed from the Population Register Centre (I-VI).
In study II, the location of the ischaemic tissue defect was registered at 
the time of the bypass operation. The location categories were: forefoot = 
ischaemic tissue loss located distal to the transmetatarsal level; midfoot and 
heel = tissue loss between the transmetatarsal and malleolar levels; crural = 
tissue loss in the crural area proximal to the malleolar level, and multiple 
level = tissue loss located in 2 or more areas (Table 9). The ischaemic tissue 
defect was classifi ed according to UTWCS in study II at the time of the bypass 
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operation. Grade was determined according to the deepest lesion. (Table 9). 
In study II, information about the duration of the ischaemic tissue defect was 
preoperatively obtained from the patient, the patient’s proxy or the referring 
physician. In studies I and II, the ischaemic tissue defects were classifi ed 
gangrenous if there was some gangrene regardless of its extent.
Infrainguinal bypass surgery
An infrainguinal bypass was performed to all patients in studies I-IV and 
VI. In study V, 761 patients had bypass surgery and 262 endovascular 
revascularisation to the crural or pedal arteries. All patients underwent 
angiography pre-operatively to evaluate the extent of arterial lesions. 
Decisions on the treatment method (bypass or PTA) had been discussed in daily 
meetings between the vascular surgeons and the interventional radiologist. The 
surgical techniques conformed to standard principles. The operating surgeon 
decided for the graft material, the position of the graft and the confi guration 
(nonreversed, reversed or in situ) of vein grafts. Bypass with a nonreversed 
translocated and devalvulated autogenous vein was prefered. Intra-operative 
heparin was administered before graft insertion. The patients received low 
molecular weight heparin during their postoperative hospital stay, in addition 
to life-long oral ASA unless contraindicated. 
Table 9. Location and UTWCS class of the ischaemic tissue lesions in the 113 legs treated 
with IBS. (II)
Location and UTWCS class n (%)
Location 
Forefoot 71 (63)
Mid- or hindfoot 13 (12)
Crural area 24 (21)
Multiple areas 5 (4)
UTWCS
1 C 41 (36)
1 D 19 (17)
2 C 10 (9)
2 D 10 (9)
3 C 10 (9)
3 D 23 (20)




All patients received intravenous antibiotics preoperatively according to the 
bacterial culture from the ischaemic tissue lesion or if no culture was available 
cefuroxime was administered intravenously. If a prosthetic graft was used, 
the patient also received intravenous vancomycin according to our hospital 
routine. Postoperative antimicrobial treatment was chosen according to the 
bacterial cultures and depending on the character of the ischaemic lesions and 
incisional wounds. Diabetics received antibiotics until complete ulcer healing 
if not contraindicated. In study VI, an infectious diseases consultant had 
evaluated every patient with a positive MDR Pa result. Patients with signs of 
MDR Pa infection, including erythema and swelling around the tissue lesion, 
infection of prosthetic material, or positive blood culture, had been treated 
with MDR Pa directed microbial therapy: a typical regimen was meropenem 
combined with amikacin or ceftazidim for at least 2 weeks.
Local wound care
Local wound care including dressings and frequency of wound care was not 
standardised. Local wound care was chosen depending on the character of the 
lesion. Sharp surgical debridement was preferred. Local ulcer surgery was 
performed, if appropriate and the type of surgery was decided depending on 
the location and character of the lesion. Deep space infection was promptly 
drained or debrided as needed and left open. Tissue defects deemed too large 
to heal within resonable time by secondary intention were closed with skin 
grafts or fl aps.
Run-off arteries
The angiographic status and run-off score of the revascularisation target artery 
were estimated in study V by the site of PTA/distal anastomosis downward 
as advised in the Ad Hoc Committee’s reporting standards (Rutherford et al. 
1997). The preoperative angiographies were retrospectively reviewed by 2 
examiners, and the angiographic status of leg and foot arteries was quantifi ed 
as follows: 0 = normal or < 20% stenosis; 1 = 20–49% stenosis; 2 = 50–99% 
stenosis; 3 = less than half of the artery occluded; and 4 = half or more of the 
artery occluded. Furthermore, in study V, angiographic run-off was categorised 
in terms of target vessel patency, also termed as in-line open continuation 
down to the pedal arteries.
Renal function
In studies III-V, renal function was described with estimated glomerular 
fi ltration rate (eGFR). eGFR (mL/min/1.73m2) was calculated from serum 
creatinine levels by using the Modifi cation of Diet in Renal disease study 
equation (Levey et al. 1999). In study V chroic kidney disease (CKD) was 
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classifi ed according to the guidelines of National Kidney Foundation; class 1 
(normal): eGFR ≥ 90, class 2 (mild): eGFR 60- 89, class 3 (moderate): eGFR 
30- 59, class 4 (severe); eGFR 15- 29, class 5 (kidney failure): eGFR < 15 
(Levey et al. 2003).
Follow-up visits
On the basis of our graft surveillance program in HUCH, routine follow-up 
visits were at 1, 6, 12 and 24 months after IBS or the latest graft intervention. 
Further investigations or leg interventions were scheduled when indicated. 
The follow-up included the following: clinical examination of the leg, duplex 
ultrasound of the vein grafts, ABI and TP measurements. In order to record 
complete data in the prospective studies I and II, the patient was called to a 
new surveillance visit whenever they did not arrive for a scheduled visit. 
The surveillance after infraopopliteal PTA included a follow-up visit at 
one month, and thereafter follow-up visits were at various time points until 
the ischaemic tissue lesion had healed. The follow-up included clinical 
examination of the leg, ABI and TP measurements. If needed, additional 
investigations were scheduled.
OUTCOME MEASURES
Study I. The complete ulcer healing time, defi ned as complete epithelialization 
of the ischaemic tissue defects and incisional wounds, was assessed and 
the infl uence of patient comorbidities on complete ulcer healing time was 
analysed. Major amputation was considered as a leg that never achieved 
complete ulcer healing. Patients with documented non-healed ischaemic 
tissue defects or non-healed incisional wounds one month before death were 
considered never to have achieved complete ulcer healing. Amputation-free 
survival with completely healed ulcers was calculated. Leg re-intervention 
rates were also assessed. 
Study II. Ulcer healing defi ned as complete epithelialization of the 
ischaemic tissue defects was analysed. The infl uence of the UTWCS class and 
the location the ischaemic tissue defect on ulcer healing time were investigated. 
The relationship between the duration of the ischaemic tissue defect before 
IBS and the healing time of the tissue lesion after IBS was evaluated. Major 
amputation was considered as a leg that never achieved ulcer healing. Patients 
with documented non-healed ischaemic tissue defects one month before death 
were considered never to have achieved complete ulcer healing.
Study III. The main aim was to assess amputation-free survival as well 
as risk factors for adverse events. AFS was defi ned as the period from IBS 
to the fi rst major amputation of the leg on which bypass was performed, or 
death from any cause, whichever occured fi rst. Survival and leg salvage were 
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also evaluated together with risk factors for major amputation and increased 
mortality. 
Study IV. The main aim was to evaluate the results of redo IBS by comparing 
tertiary graft patency with secondary graft patency rates and by calculating the 
patency-leg salvage gap. Graft patency was defi ned according to the criteria 
prepared by the Ad Hoc Committee on reporting standars (Rutherford et al. 
1997). The state of graft patency as determined during the most recent follow-
up visit was used for analysis. 
Study V. Bypass surgery to the infrapopliteal arteries was compared 
with PTA. The main outcomes were mortality, major amputation, AFS, and 
freedom from any further revascularisation. Further revascularisation was 
divided into two categories: maintenance procedures performed to support the 
primary revascularisation (including thrombolysis, thrombectomy, PTA of the 
graft, interpositions, patch angioplasties, distal extention grafts for the bypass 
group and PTA for stenosis or occlusions in the PTA group) and freedom from 
surgical revascularisation (including bypass operations with new grafts). 
Study VI. Leg salvage, survival, AFS, graft patency, and reintervention 
rates of the MDR Pa group were compared with those of the control group. 
STATISTICAL ANALYSES
The statistical analyses were performed using the Statistical Package for the 
Social Sciencies (SPSS), version 13.0 (I), version 15.0 (II, V), and version 
16.0 (III, IV, VI) Chicago, Illinois, USA. 
Associations between categorical data were analysed with the Chi-square 
test or the Fisher’s Exact-test when appropriate (V, VI). Differences between 
two groups with respect to ordinal variables were tested with the Mann-
Whitney U-test (V). The normality of distributions was established with the 
Kolmogoroff-Smirnoff goodness of fi t test. The Mann-Whitney U-test was 
applied for comparison of continuous variables between two non-normally 
distributed groups (V, VI). Correlation analysis was done by calculating the 
Spearman’s rank correlation coeffi cient (II).
Logistic regression with backward selection was performed to calculate the 
risk, the so-called propensity score, of patients to be included in bypass surgery 
or PTA group (V). The variables having a p < 0.2 in univariate analysis were 
included in the regression model (V). Hosmer-Lemeshow’s test was used to 
assess the regression model fi t. Receiver operating characteristic (ROC) curve 
was employed to estimate the probability of patients being included in the 
different treatment groups (V). The calculated propensity score was employed 
for adjusting for other variables in estimating their impact on the postoperative 
outcome in multivariate analysis and for one-to-one matching. One-to-one 
propensity score matching between study groups was done according to a < 
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0.005 difference in the propensity score between each patient of the bypass 
surgery and PTA group (V).
Survival analyses were performed using the Kaplan-Meier method and Cox 
regression model (I-VI). Patency, survival, leg salvage, patients alive with 
leg and ulcer healing time were calculated using the Kaplan-Meier method. 
Survival data obtained in the Kaplan-Meier analyses were compared using the 
log rank test (I-VI). The Cox multiple regression analysis was applied to study 
the differences between groups to adjust for potential confounding factors 
(I-V). Cox regression analysis provided estimates of survival propabilities 
and hazard ratios of clinically relevant factors for leg salvage, ulcer healing, 
survival and AFS. The Chi- square test was used to compare leg salvage, 
survival and AFS rates between two groups at specifi c time points (1 year) 
during the follow-up period (VI).
Statistically signifi cant differences were given with p-values ≤ 0.05. In the 
survival analyses of studies I and V a p-value less than 0.05 was considered 
signifi cant.




COMPLETE ULCER HEALING TIME (I)
Complete ulcer healing time, including both healing of the ischaemic tissue 
defects and incisional wounds is a slow process even after a successful 
infrainguinal bypass. 27% of the patients achieved complete ulcer healing 
within 3 months, 40% within 6 months, and 75% within 12 months (Figure 
7). The median time to complete ulcer healing was 190 days (range from 11 
days to > 365 days). Diabetes was an independent risk factor for prolonged 
complete ulcer healing time (Table 10). The healing rates were 26% for 
diabetics and 53% for non-diabetics at 6 months, and 63% and 87% at 12 
months, respectively (Figure 8). The median complete ulcer healing time was 
213 days for diabetics compared to 159 days for non-diabetics. 
The amputation-free survival with completely healed ulcers was attained 
only in 50% of patients at one year after IBS due to the prolonged ulcer healing 
time and the relatively high mortality rate (27% at 1 year). Only 3% (n = 5) 
patients were lost during the follow-up.
ADDITIONAL INTERVENTIONS TO ACHIEVE COMPLETE ULCER HEALING (I)
The infrainguinal bypass grafting was seldom the only surgical procedure 
in the treatment of the critically ischaemic leg. In order to maintain graft 
patency or to treat recurrent ischaemia, 21% (n = 31) of the legs required 
vascular reintervention during the fi rst post-operative year after IBS. In total, 
39 vascular reinterventions were performed on 31 legs; 14 had PTA of the 
graft, 12 had surgical revison of the conduit (including thrombectomy, patch 
angioplasty, interposition grafts, and distal extension grafts), 10 had PTA to 
the infl ow or outfl ow artery, one had thrombolysis, one had redo IBS with a 
new graft, and one had embolization of an arteriovenous fi stula.
Local ulcer surgery in the operating theatre was performed to the ischaemic 
tissue defects in 73 legs (49%) during the one-year follow-up. In total, 119 
local surgical procedures, including minor amputations and revisions (n = 89), 
skin graftings (n = 25), local/free fl ap transfers (n = 3) and calcaneal resections 
(n=2), were performed for treating of the ischaemic tissue defects. 
The incisional wound required surgery in 15% of the legs (n = 23) because 
of haematoma or infection.
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Figure 7. Kaplan-Meier curve demonstrating the healing time of the ischaemic tissue 
lesions and incisional wounds after infrainguinal bypass surgery for CLI Fontaine IV. (I)
Table 10. Uni- and multivariate analysis of factors related to complete healing of 
ischaemic ulcers and incisional wounds in 150 legs treated with infrainguinal bypass 
due to CLI Fontaine IV. (I)
Univariate analysis Multivariate analysis
Factor p-value HR (95% CI)      p-value
Age > 80 years 0.295 0.9 (0.6-1.7)      0.912
BMI > 25 0.470 1.0 (0.6-1.6)      0.964
Cerebrovascular disease 0.729 0.9 (0.5-1.8)      0.830
Chronic pulmonary disease 0.704 0.9 (0.5-1.7)      0.840
Coronary artery disease 0.511 1.2 (0.8-2.0)      0.397
Diabetes mellitus 0.001 0.5 (0.3-0.8)      0.006
ESRD with dialysis 0.170 0.4 (0.1-3.1)      0.392
BMI: body mass index (kg/m2)
ESRD: end stage renal disease
soderstrom_vaitoskirja_korj.indd   56 19.9.2011   11:16:59
57
RESULTS
INFLUENCE OF LOCAL CHARACTERISTICS OF THE ISCHAEMIC TISSUE 
DEFECTS ON THE ULCER HEALING TIME (II)
Location
The location of the ischaemic tissue defects in the leg infl uenced ulcer healing 
time. Ischaemic tissue defects located in the mid- and hindfoot had signifi cantly 
prolonged ulcer healing time (hazard ratio [HR] 0.4, 95% CI 0.1-0.9, p = 0.044). 
At 3 months after the bypass surgery 9% of the ischaemic tissue defects in the mid- 
and hindfoot area had healed, at 6 months 19% and at 12 months 49% (Figure 9). 
The corresponding healing rates for forefoot lesions were 42%, 51% and 78%, 
and for crural lesions 30%, 50% and 72%. The overall ulcer healing rate for all 
ischemic tissue defects were 26 % at 3 months, 47% at 6 months and 74% at 12 
months. 
The UTWCS class 
None of the UTWCS classes had a predictive effect on the ulcer healing time 
after IBS (Table 11). Neither UTWCS stage nor grade predicted ulcer healing 
time alone. The healing rate for non-infected ischaemic tissue defects (stage 
Number of legs under surveillance (No of legs with unhealed ischaemic ulcers or incisional wounds) :
Non-diabetics
76 (76) 61(37) 55 (23) 52 (7) 49 (5)
Diabetics
74 (74) 53(44) 50 (34) 45 (17) 43 (14)
Figure 8. Diabetics showed prolonged healing time of the ischaemic ulcers and 
incisional wounds after IBS (Kaplan Meier plot). (I)
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C) was 76% at 1 year, and for infected ischaemic tissue defects (stage D) 67% 
at 1 year, p = 0.575. The ulcer healing time did not increase with increasing 
depth of the ischaemic tissue defect.
Gangrene
Ulcer healing rate at 1 year was 76% for gangrenous tissue defects compared 
to 75% for ischaemic ulcerations, p = 0.353. 
INFLUENCE OF DURATION OF THE ISCHAEMIC TISSUE DEFECT ON THE 
ULCER HEALING TIME (II)
The median duration of the ischaemic tissue defect before IBS was 68 days, range 
6–1154 days. There was not a correlation between duration of the ischaemic tissue 
defect before IBS and the healing time after bypass surgery (Spearman’s r = 0.138, 
p = 0.267) (Figure 10).
Figure 9. Healing times of ischaemic tissue defects after IBS according to diff erent 
locations of the defect. Asterisk (*) indicates that the standard error of the estimate was 
over 10%. (II)
Legs under surveillance (n):
 113 96 87 82 80
Legs with unhealed ischaemic tissue defects located in:
forefoot 71 40  24 14 8
mid/hindfoot  13  10  7 6 3*
crural area 24 14  9 5 5*
multiple areas  5 3* 2* 1* 1*
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RESULTS
U T W C S Ulcer healing
grade stage Multivariate analysis






1.0                                      0.559
D 
infected ischaemic
1.1 (0.5-2.3)                      0.754
2 
defects extending 




0.5 (0.2-1.4)                      0.193
D 
infected ischaemic







1.3 (0.6-3.0)                      0.535
D 
infected ischaemic
0.9 (0.4-1.7)                      0.669
Table 11. Cox regression analysis showing the relationship between the University 
of Texas Wound Classifi cation System (UTWCS) classes and the healing time of the 
ischaemic tissue defects after IBS. Non-infected dermal ischaemic tissue defect (1C) was 
the reference class. (II)
Figure 10. Scatter plot demonstrating the duration of the ischemic ulcer before 
infrainguinal bypass surgery (IBS) and healing time of the ischaemic tissue lesions after 
IBS. There was no correlation between duration and healing time of the ischaemic tissue 
defects. (Spearman’s r = 0.138, p = 0.267). (II)
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AMPUTATION-FREE SURVIVAL AFTER IBS FOR ISCHAEMIC TISSUE LOSS (III)
The AFS for patients with ischaemic tissue loss was poor in the long-term 
folllow-up mainly due to high mortality rate. Leg salvage rates were high in 
long-term follow-up. 
Amputation-free survival
At 1 month after IBS 87% of the patients were alive with a salvaged leg. At one 
year the AFS rate was 55% (Figure 11). The AFS was 40% at 3 years and 30% 
at 5 years. Coronary artery disease, low eGFR indicating renal insuffi ciency, 
gangrene and high age were all independently associated with decreased AFS 
(Table 12 and Figure 12). Diabetes was associated with decreased AFS in 
univariate analyses but not in multivariate analysis. 
Leg salvage 
The leg salvage rate was 94% at 1 month, 83% at 1 year, 80% at 3 years, and 
76% at 5 years. Gangrene and renal insuffi ciency measured by eGFR were 
independent risk factors for major amputation (Table 12). 
Survival
The survival rate was 93% at 1 month, 71% at 1 year, 53% at 3 years, and 38% 
at 5 years. High age, renal insuffi ciency (eGFR) and chronic pulmonary disease 
were associated with increased mortality in multivariate analyses (Table 12). 
Figure 11. One-year outcome after IBS in patients with CLI and tissue loss (Fontaine IV). (III)
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Figure 12. Kaplan-Meier survival curves demonstrating patients who were alive without major 
amputation after infrainguinal bypass grafting performed for ischaemic ulcers and gangrene. 
Patients with gangrene had a signifi cantly decreased AFS as compared to those with ischaemic 
ulcers (log rank p = 0.016). The standard error was under 5% throughout the time interval 
analysed. (III)
Table 12. Uni- and multivariate analysis of factors related to major amputation, death and decreased 
amputation-free survival after infrainguinal bypass surgery for ischaemic tissue loss. (III)
 
UNIVARIATE ANALYSIS a 
  Major amputation      Mortality Decreased amputation-
free survival 
Factor       p-value        p-value            p-value 
Cerebrovascular disease  
Chronic pulmonary disease   
Coronary artery disease        
Diabetes mellitus                   
Indication (gangrene) Sex       
 
      0.875 
      0.244 
      0.440 
      0.156 
      0.004 
      0.842 
       0.616 
       0.049 
     <0.001 
       0.099 
       0.212 
       0.077 
           0.520 
           0.027 
         <0.001 
           0.005 
           0.016 
           0.281 
 
MULTIVARIATE ANALYSIS b 
 Major amputation Mortality Decreased amputation-
free survival 
Factor HR  (95% CI )   p-value HR  (95% CI)    p-value HR  (95% CI)     p-value 
Age 
Cerebrovascular disease 
Chronic pulmonary disease    





0.99 (0.97-1.01)  0.218 
1.08 (0.66-1.76)  0.757 
1.66 (0.99-2.81)  0.055 
1.05 (0.70-1.56)  0.831 
1.08 (0.72-1.61)  0.718 
0.99 (0.97-0.99)  0.018 
1.90 (1.25-2.89)  0.003 
0.99 (0.67-1.49)  0.986 
1.03 (1.02-1.04) <0.001 
1.03 (0.78-1.35)  0.850 
1.35 (1.02-1.79)  0.037 
1.23 (0.98-1.53)  0.075 
1.08 (0.87-1.33)  0.491 
0.99 (0.98-0.99) <0.001 
1.14 (0.89-1.47)  0.307 
1.16 (0.94-1.43)  0.180 
1.02 (1.01-1.03)  <0.001 
1.01 (0.78-1.31)    0.937 
1.41 (1.08-1.85)    0.012 
1.26 (1.02-1.55)   0.035 
1.06 (0.86-1.30)   0.583 
0.99 (0.98-0.99)  <0.001 
1.36 (1.07-1.72)    0.012 
1.17 (0.96-1.44)    0.116 
 a) Kaplan-Meier analysis  b) Cox regression  
 HR=risk ratio,   CI=confidence interval,  eGFR: estimated glomerular filtration rate (mL/min/1.73m 2) 
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RESULTS OF REDO IBS (IV)
Graft stenosis and occlusions were not unusual events after IBS (Table 13). 
Secondary patency rate was 75% at 1 year and 61% at 5 years. Thrombolysis 
and thrombectomy, with or without graft revision, were therapeutic options 
in case of an occlusion of an infrainguinal bypass, thereby allowing for 
secondary patency when successful. The present series focused on those 
patients who were not considered to be suitable for these procedures due to a 
lengthy graft occlusion time and who therefore were treated with completely 
new bypasses. Ultimately, during the follow-up in this study, 144 of the 651 
primary infrainguinal bypass grafts failed. 32% (46 legs) with failed grafts 
underwent redo infrainguinal bypasses with new grafts. 41 legs had redo 
IBS once, 4 legs twice and 1 leg three times. (Table 14). The median time 
between the failure of the original infrainguinal graft and the installation of a 
completely new bypass was 24 days, range 0-910 days. Tertiary patency rate, 
defi ned as the whole period of time with a patent infrainguinal graft in a leg, 
was 82% at 1 year and 70% at 5 years (Table 13). The tertiary patency rate was 
signifi cantly higher than the secondary graft patency rate, p = 0.003 (Figure 
13). The leg salvage rates were 83% at 1 year, 80% at 3 years, and 78% at 5 
years. There was no signifi cant difference between tertiary patency rate and 
leg salvage (p = 0.281) (Figure 14). 
In subgroup analysis, the leg salvage rates for patients who did not undergo 
redo bypass surgery for the treatment of graft failure were 48% at 1 year after 
graft failure and 36% at 5 years. Redo bypass surgery for treatment of failed 
grafts and CLI yielded signifi cantly higher leg salvage rates; 86% at 1 year, 
and 84% at 5 years (p < 0.001) (Figure 15). Reasons for not performing redo 
bypass surgery for graft failure included one or several of the following: poor 
or absent target outfl ow artery, extensive tissue defects, severe comorbidities, 
lack of suitable autologous vein grafts, immobility, patients refusal. Moreover, 
10% (n = 14) of the legs with failed grafts did not require any interventions 
because the ischaemic tissue defect had healed. 
PATENCY 1 month 6-month 1-year 2-year 3-year 4-year 5-year
Primary 88 70 61 49 47 46 46
Primary 
assisted
93 79 73 65 63 59 57
Secondary 95 81 75 68 65 63 61
Tertiary 96 86 82 78 76 71 70
Table 13. Patency rates (%) of the infrainguinal bypass grafts reconstructed for ischaemic 
tissue loss. (IV)
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n (%) n  (%) 
   Infl ow artery
Male 29 (64) Common femoral artery 41 (78)
ABI , median (range) 0.36 (0-
1.00)
Deep femoral artery 1 (2)
Age, median (range) 71 (42-82) Superfi cial femoral 
artery
6 (12)
Cerebrovascular disease 11 (24) Proximal popliteal artery 2 (4)
Chronic pulmonary disease 7 (16) Distal popliteal artery 2 (4)
Coronary artery disease 30 (67) Outfl ow artery
Diabetes mellitus 20 (44) Distal popliteal artery 12 (23)
eGFR , median (range) 76 (36-139) Tibioperoneal trunk 2 (4)
Hyperlipidemia 20 (44) Anterior tibial artery 14 (27)
Hypertension 29 (64) Posterior tibial artery 7 (13)
Peroneal artery 14 (27)
Dorsal pedal artery 2 (4)
Plantar artery 1 (2)
Graft material
Prosthesis 7 (13)
Composite graft 4 (8)
Leg vein 14 (27)
Arm vein 27 (52)
Spliced vein graft 21 (40)
Table 14. Demographics of the 45 patients (46   legs) who has redo bypass surgery and 
the details of the 52 redo infrainguinal bypass grafts. (IV)
Figure 13. Secondary and tertiary patency rates after IBS for CLI with tissue loss (Kaplan-
Meier plot, log rank p = 0.003). The standard error was under 5% throughout the time 
interval analysed. (IV)
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INFRAPOPLITEAL BYPASS VERSUS PTA (V)
Overall series
In the overall series, bypass surgery and PTA to the infrapopliteal arteries 
achieved similar long-term results. At 5 years, the leg salvage rates were 76% 
vs. 75% (p = 0.78), survival rates 43% vs. 48% (p = 0.53), and amputation-free 
survival rates 37% vs. 38% (p = 0.81). Freedom from any revascularisation 
was similar in the study groups (74% vs. 77% at 5 years, p = 0.47), whereas 
freedom from surgical revascularisation was signifi cantly higher after bypass 
surgery (94% vs. 86% at 5 years, p < 0.001) (Table 15).
Propensity score analysis 
The variables included in the logistic regression model for the calculation of 
the propensity score are listed in Table 16. Pulmonary disease (β-coeffi cient 
-0.726), diabetes (β-coeffi cient -0.703), cerebrovascular disease (β-coeffi cient 
-0.425), smoking habit (β-coeffi cient 0.538), estimated glomerular fi ltration 
rate (β-coeffi cient β -0.182), leg status (rest pain vs. ulcer or gangrene, 
β-coeffi cient -1.645), target segment (leg vs. foot arteries β-coeffi cient 3.650), 
previous revascularisation procedure on the same segment (β-coeffi cient 
0.818), and patent target vessel downward to the pedal artery (β-coeffi cient 
1.137) were independent predictors for assigning patients with CLI to either 
Figure 14. There was no signifi cant diff erence between tertiary patency rates and leg 
salvage rates after IBS for CLI with tissue loss (Kaplan-Meier plot, log rank p = 0.281). The 
standard error was under 5% throughout the time interval analysed. (IV)
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the PTA or the bypass surgery group (constant β-coeffi cient 2.354, Hosmer-
Lemeshow’s test, p = 0.372). The obtained propensity score had an area of 
0.82 under the ROC curve (95% CI 0.79- 0.84, p < 0.001).
Results of infrapopliteal PTA versus bypass surgery according to 
propensity score analysis
One-to-one propensity score matching provided 208 pairs of patients who 
underwent either bypass surgery or PTA (Table 16). The postoperative 
outcomes in these propensity-score-matched pairs are summarized in Table 
17. AFS estimates in propensity-matched pairs are shown in Figure 16. In 
these propensity-score-matched pairs, there were no signifi cant differences 
between bypass surgery and PTA in terms of leg salvage at 5-year follow-
up (69% vs. 74%, p = 0.11), survival (40% vs. 46%, p = 0.44), AFS (30% 
vs. 37%, p = 0.26) and freedom from any revascularisation procedure (70% 
vs. 77%, p = 0.17). Bypass surgery was associated with signifi cantly higher 
freedom from surgical revascularisation (91% vs. 85% at 5 years, p = 0.045).
In the overall series, when treatment method was adjusted for propensity 
score, no signifi cant difference was observed in terms of leg salvage (p = 0.19), 
survival (p = 0.17), AFS (p = 0.28) or freedom from any revascularisation (p 
= 0.60). However, freedom from surgical revascularisation was signifi cantly 
higher in the bypass group (p = 0.004).
Figure 15. Kaplan-Meier curves demonstrating leg salvage in patients with failed 
primary infrainguinal bypass graft. Patients undergoing redo bypass surgery with new 
grafts achieved good leg salvage whereas the leg salvage in patients with no redo 
bypass surgery was poor (log rank p < 0.001). (IV)
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30-day 1-year 3-year 5-year p-value
Survival 0.53
PTA 97% (245) 73% (155) 55% (73) 48% (34)
Bypass surgery 94% (712) 76% (481) 57% (283) 43% (129)
Leg salvage 0.78
PTA 96% (237) 86% (135) 77% (56) 75% (25)
Bypass surgery 94% (673) 82% (422) 79% (246) 76% (111)
Amputation-free survival 0.81
PTA 93% (237) 64% (135) 44% (57) 38% (25)
Bypass surgery 89% (673) 66% (422) 49% (246) 37% (111)
Freedom from any 
revascularisation
0.47
PTA 95% (234) 79% (124) 77% (55) 77% (27)
Bypass surgery 92% (657) 80% (378) 75% (195) 74% (89)
Freedom from bypass 
surgery
<0.001
PTA 96% (236) 87% (135) 86% (60) 86% (31)
Bypass surgery 99% (707) 96% (458) 94% (261) 94% (122)
Table 15. Kaplan-Meier’s estimates of early and late outcome in the overall series Patients 
undergoing infrapopliteal bypass surgery is compared with patients undergoing 
infrapopliteal PTA for CLI. The numbers of patients entering intervals are reported in 
parentheses. (V)
Late outcome after isolated infrapopliteal revascularisation 
374 patients underwent isolated infrapopliteal revascularisation. Popliteodistal 
bypass was performed for 176 patients and PTA for 198. In the overall series, 
PTA was associated with signifi cantly better leg salvage as compared to bypass 
surgery (76% vs. 68% at 5 years, p = 0.04), but not survival (47% vs. 40% at 5 
years, p = 0.27). AFS was similar after PTA and bypass surgery (34% vs. 33% 
at 5 years, p = 0.58). Bypass was associated with signifi cantly higher freedom 
from surgical revascularisation (86 % vs. 96% at 5 years, p = 0.001) whereas 
freedom from any revascularisation was similar (79 % vs. 85% at 5 years, p 
= 0.17).
The propensity score for this subgroup of patients who underwent isolated 
infrapopliteal revascularisation was calculated and its area under the ROC 
curve was 0.76 (95% CI 0.71–0.81, p < 0.001, Hosmer-Lemeshow’s p = 
0.13). 
One-to-one propensity score matching provided 89 pairs of patients who 
underwent isolated infrapopliteal revascularisation. When bypass was compared 
soderstrom_vaitoskirja_korj.indd   66 19.9.2011   11:17:00
Overall series



















Age (years)* 75±11 74±11 0.18 74±11 74±11 0.63
Females 158 (60) 431 (57) 0.30 125 (60) 111 (53) 0.20
Pulmonary disease* 41 (16) 86 (11) 0.07 23 (11) 20 (10) 0.63
Diabetes* 194 (74) 417 (55) <0.001 154 (74) 157 (76) 0.74
Dyslipidemia* 116 (44) 286 (38) 0.07 90 (43) 76 (37) 0.17
Hypertension* 204 (78) 557 (73) 0.14 163 (78) 152 (73) 0.21
Coronary artery disease 174 (66) 492 (65) 0.64 134 (64) 146 (70) 0.21
Cerebrovascular disease* 63 (24) 135 (18) 0.03 46 (22) 48 (23.1) 0.82
Smoking habit #* 32 (12) 163 (21) 0.001 28 (13) 29 (14) 0.89
Previous lower limb 
revascularisation
23 (9) 145 (19) <0.001 17 (8) 15 (7) 0.71
Previous revascularisation 
on the same segment*
10 (4) 78 (10) 0.001 8 (4) 5 (2) 0.58
Serum creatinine (μmol/l) 143±140 123±124 0.001 135±132 135±145 0.44
eGFR (mL/min/1.73 m2)* 62±31 70±34 0.001 64±31 65±30 0.60
CKD classes 0.04 0.83
1 43 (16) 185 (24) 39 (19) 46 (22)
2 93 (36) 267 (35) 74 (36) 69 (33)
3 88 (34) 233 (31) 69 (33) 71 (34)
4 18 (7) 42 (6) 13 (6) 9 (4)
5 20 (8) 34 (5) 13 (6) 13 (6)
Indication* <0.001 0.45
Rest pain 17 (7) 206 (27) 15 (7) 13 (6)
Ulcer 199 (76) 438 (58) 158 (76) 150 (72)
Gangrene 46 (18) 117 (15) 35 (17) 45 (22)
Angiographic score 6.9±1.7 6.9±2.5 0.47 6.8±1.6 6.6±1.3 0.019
Target vessel patent down 
to the pedal arteries*
136 (52) 622 (82) <0.001 122 (59) 122 (59) 1.00
Target level* <0.001 1.00
Crural arteries 260 (99) 584 (77) 206 (99) 205 (99)
Foot arteries 2 (1) 177 (23) 2 (1) 3 (1)
Most distal target artery <0.001 <0.001
Tibioperoneal trunk 47 (18) 13 (2) 38 (18) 6 (3)
Anterior tibial artery 83 (32) 214 (28) 70 (34) 74 (36)
Posterior tibial artery 39 (15) 168 (22) 31 (15) 44 (21)
Fibular artery 91 (35) 189 (25) 67 (32) 81 (39)
Dorsalis pedis artery 2 (1) 153 (20) 2 (1) 3 (1)
Plantar artery 0 (0) 24 (3) 0 (0) 0 (0)
Concomitant
femoropoliteal repair 65 (25) 565 (74) - 45(22) 168 (81) -
Bypass graft - -
Vein graft - 717 (94) - 198 (95)
Prosthetic graft - 44 (6) - 10 (5)
* variable included in the regression model for estimation of the propensity score
# Current smoker or smoker last 5 years
CKD classes: Chronic kidney disease classes according to estimated glomerular fi ltration rate (eGFR ml/
min/1.73 m2); class 1 (normal): eGFR ≥ 90; class 2 (mild): eGFR 60-89; class 3 (moderate): eGFR 30-59; class 4 
(severe); eGFR 15-29, class 5 (kidney failure): eGFR < 15
Table 16. Baseline characteristics and operative data on patients who underwent infrapopliteal 
bypass surgery and infrapopliteal PTA for CLI. Data are reported for the overall study population 
and for one-to-one propensity-score-matched pairs. (V)
soderstrom_vaitoskirja_korj.indd   67 19.9.2011   11:17:01
68
to PTA, there were no signifi cant differences in leg salvage (69% vs.79%, p = 
0.12), survival (36% vs. 39%, p = 0.89) or AFS (30% vs. 31%, p = 0.82) in the 
5-year follow-up. Freedom from any revascularisation was also similar (84% 
vs. 82%, p = 0.60). Bypass was associated with signifi cantly higher freedom 
from surgical revascularisation (93 % vs. 86% at 5 years, p = 0.03).
In the overall isolated infrapopliteal series, when treatment method was 
adjusted for the propensity score, PTA was associated with better leg salvage 
(p = 0.04), but bypass was associated with signifi cantly better freedom from 
surgical revascularisation (p = 0.002). Survival (p = 0.27), amputation-free 
survival (p = 0.78) and freedom from any revascularisation (p = 0.17) were 
similar in the study groups.
THE OUTCOME IN CLI PATIENTS WITH MDR Pa CONTAMINATION (VI)
During the MDR Pa outbreak of 2000-2001 in our vascular ward in HUCH, 
64 patients undergoing IBS for CLI were contaminated with MDR Pa. In 
30-day 1-year 3-year 5-year p-value
Survival 0.44
PTA 97% (194) 74% (124) 55% (57) 46% (24)
Bypass surgery 97% (199) 76% (131) 55% (78) 40%( 38)
Leg salvage 0.11
PTA 97% (191) 87% (110) 77% (44) 74% (17)




PTA 94% (189) 66% (110) 43% (44) 37% (17)
Bypass surgery 89% (183) 61% (107) 42% (61) 30% (30)
Freedom from any 
revascularisation
0.17
PTA 95% (185) 78% (96) 77% (41) 77% (18)




PTA 96%(186) 86% (106) 85%(46) 85%(22)
Bypass surgery 99% (196) 92% (120) 91% (69) 91% (35)
Table 17. Kaplan-Meier’s estimates of early and late outcome in 208 propensity score 
matched pairs. Patients having infrapopliteal bypass surgery are compared with patients 
having infrapopliteal PTA for CLI The numbers of patients entering intervals are reported 
in parentheses (V).
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short-term follow-up he MDR Pa outbreak increased the risk for life or leg 
loss in patients undergoing leg salvage surgery. 
The MDR Pa was initially cultured most frequently from the incisional 
wound (n = 30, 47%). The initial positive MDR Pa was obtained from the 
ischaemic tissue defect in 36% of the patients (n = 23). 14% (n = 9) of the 
patients had a positive MDR Pa-culture before the bypass surgery and 86% (n 
= 55) after the bypass surgery. Median time between positive MDR Pa-culture 
and IBS was 14 days after IBS (range from 56 days before IBS to 246 days 
after IBS). 43 patients with MDR Pa (66%) had signs of a MDR Pa infection 
and were treated with intravenous MDR Pa –directed microbial therapy. A 
sensitive P. aeruginosa was cultured from the ischaemic ulcers or incisional 
wounds in 31 patients (48%) of the control group. 
Figure 16. Amputation-free survival after bypass surgery and PTA to the infrapopliteal 
for CLI in 208 propensity score matched pairs (Kaplan-Meier survival curves). (V)
Patients at risk
Bypass group
208 107 76 61 49 30
PTA group
208 110 69 44 31 17
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At one year, AFS was signifi cantly poorer in patients with MDR Pa (52% 
vs. 75%, p = 0.020). Long-term AFS was low in both groups. Five years after 
IBS only 29% of the MDR Pa patients and 32% of the control patients were 
alive with the revascularized leg (p = 0.144) (Figure 17). 
Leg salvage was 79% for the MDR Pa group at 1 year, compared to 92% 
for the control group (p = 0.078). The 5-year leg salvage rates were 87% and 
73%, respectively (p = 0.126). Survival was 69% for the MDR Pa group at 1 
year, and 82% for the control group (p = 0.063). The 5-year survival was 36% 
for both groups. The 1-year assisted primary graft patency rate was lower in 
the MDR Pa group compared to the control group (67% vs. 77%, p = 0.049) 
whereas the primary (60% vs. 64%, p = 0.222) and secondary patency rates 
(72% vs. 81%, p = 0.149) were similar.
Five of the eight prostheses (63%) were infected by MDR Pa and removed 
due to the infection. No prosthesis was infected or removed in the control 
group. The number of patients having vascular re-interventions in both groups 
was similar (17 in the MDR Pa vs. 19 in the control group, p = 0.694).
Local surgical interventions to the incisional wounds and ischaemic tissue 
defects were performed in signifi cantly more patients in the MDR Pa group 
than in the control group (63% vs. 33%, p = 0.002).
Figure 17. Kaplan-Meier survival curve demonstrating the amputation-free survival in 
the MDR Pa group and the control group during the 5-year follow-up (log rank p=0.144). 
At 1 year after the bypass, patients with MDR Pa showed signifi cantly decreased 
amputation-free survival (Chi-square test p = 0.02).




LIMITATIONS OF THE STUDY
The healing time of the ischaemic tissue defects and incisional wounds in 
studies I and II may have been overestimated because the status of the lesions 
was checked intermittently. However, it is worth to note that some patients 
had additional follow-up visits to those scheduled at 1, 6 and 12 months due 
to reinterventions and slow ulcer healing. The diversity of wound care might 
have infl uenced the healing time as the wound care was not standardised. 
Wound care was continued in a number of other facilities outside HUCH. 
The assessment of the grade of the ischaemic tissue lesion appeared diffi cult 
in study II especially if the lesion was covered with a dry fi brous eschar not 
necessitating debridement. Due to the small sample size in each UTWCS 
subgroup, study II was prone to a type two statistical error. Furthermore, the 
size of the ischaemic tissue defects may infl uence ulcer healing time, but size 
was not included in our analysis.
The patency periods were underestimated due to the fact that graft 
patencies were checked intermittently. The patency data were not as complete 
as the major amputation and mortality data. Amputation and mortality data 
could also be collected from national registries whereas patency data required 
vascular investigations. Patients with CLI are old and usually have several 
comorbidities, which was probably the main reason why the graft surveillance 
was incomplete.
There were feasibility issues that could not be addressed in the present 
analysis when comparing PTA and bypass in study V. The most important of 
them was the fact that the character of the arterial lesion treated could not be 
included in the analysis due to the lack of proper classifi cation. 
The infl uence of other bacteria than MDR Pa was not investigated in study 
VI. In some patients the positive MDR Pa result might have infl uenced the 
treatment strategy. The relatively small number of patients with MDR Pa 
prevented the drawing of defi nitive conclusions. 
There may be a certain level of inaccuracy regarding the information on 
the comorbidities and patency data, which were retrieved from the HUSVasc 
registry and patientsí records in studies III-VI due to the retrospective nature 
of the studies.
GENERAL DISCUSSION
In most reports dealing with CLI, the outcomes of patients with rest pain 
are grouped with outcomes of those with tissue loss. Indeed, Taylor et al. 
(2009) questioned the accuracy of all data for CLI, where rest pain and 
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tissue loss is mixed and reported as a single outcome. They studied lower 
limb revascularisations and showed that the indication affects the outcome. 
Secondary patency, leg salvage, survival and amputation-free survival were 
poorer in patients with ischaemic tissue loss compared to rest pain. As CLI 
with tissue loss (Fontaine IV) is a more advanced form of peripheral arterial 
disease than rest pain (Fontaine III), it is reasonable to believe that patients 
with a more advanced disease would achieve an inferior outcome after IBS 
than those with a less advanced disease. In this study, we focused on patients 
with CLI and tissue loss (Fontaine IV) undergoing infrainguinal bypass 
surgery.
Healing of ischaemic tissue defects and incisional wounds
Our prospective studies revealed that complete ulcer healing is a slow 
process even after successful IBS. Less than half of the patients achieved 
complete healing of the ischaemic tissue defects and the incisional wounds 
within a period of 6 months after bypass surgery and at one year the overall 
healing rate was not more than 75%. Complete ulcer healing has seldom been 
analysed in CLI-studies (Hoffman et al. 2007) although already in 1999 the 
Trans-Atlantic Conference on clinical trial guidelines in peripheral arterial 
occlusive disease recommended that complete ulcer healing should be a 
primary endpoint for the treatment of CLI (Labs et al. 1999). Less than 1% 
of CLI-studies have provided data on complete ulcer healing (Hoffman et al. 
2007). Chung et al. (2006) reported very similar healing rates as we observed 
whereas some other studies have reported higher healing rates (Nicoloff et 
al. 1998, Berceli et al. 1999, Wölfl e et al. 2003). Reporting mean and median 
healing time gives a possibility to exclude non-healing ulcers. Healing rate at 
one year, as in this study, provides clear information. Comparing the studies 
that analyse complete ulcer healing time is diffi cult since the studies differ 
according to inclusion criteria, variability of follow-up or the measurement 
of ulcer healing (Nicoloff et al. 1998, Berceli et al. 1999, Chung et al. 2006). 
Several studies report healing rates without separating the results from 
different treatment modalities (Konradsen et al. 1996, Treiman et al. 2000, 
McCulloch et al. 2003, Tautenhahn et al. 2008). Despite these differences, 
the studies clearly show that ulcer healing time is measured in months rather 
than weeks (Konradsen et al. 1996, Nicoloff et al.1998, Berceli et al. 1999, 
Treiman et al. 2000, Wölfl e et al. 2003, Goshima et al. 2004, Chung et al. 
2006). 
The widespread atherosclerosis in these CLI-patients may be a major 
factor behind the slow healing process. Of the comorbidities we identifi ed 
diabetes mellitus as the dominant risk factor for prolonged complete ulcer 
healing time. Accordingly, Goshima et al. (2004) also reported prolonged 
ulcer healing times for patients with diabetes. In contrast, Wölfl e et al. (2003) 
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reported similar healing rates of ischaemic tissue lesions in patients with and 
without diabetes. They, however, included only patients available for one-
year follow-up with patent grafts, which of course caused selection bias. 
Diabetes was an independent risk factor for wound infections after surgery 
for CLI in the study by Virkkunen et al. (2004). The mechanism behind the 
impaired healing process in diabetics is not clearly understood. Vascular, 
neuropathic, immunogenic and biochemical abnormalities have been 
proposed to contribute to a diminished capacity for tissue repair in diabetics 
(Greenhalgh 2003). 
Several publications have suggested that the presence of renal failure 
interferes with the healing of tissue defects and that patients with renal failure 
may ultimately require major amputation (Sanchez et al. 1992, Peltonen et 
al. 1998, Treiman et al. 2000). In the present study the very small number of 
patients with ESRD prevents fi rm conclusions. In this study, as in the series 
published by Chung et al. (2006) and Goshima et al. (2004) end stage renal 
disease was associated with major amputation and death which might have 
masked the effect on complete ulcer healing time. 
Our study revealed that the location of the ischaemic tissue affects the 
healing time of the ischaemic defect. Tissue defects located in the midfoot and 
heel area healed more poorly than forefoot and crural lesions. The poor healing 
could be explained by factors on the background of lesions located in the heel, 
such as the poor general condition causing bed rest. Radical debridement of 
devital tissue may be problematic in the midfoot and heel area compared to 
the forefoot. Further coverage of defects on calcaneus bone or weight bearing 
surfaces in midfoot and heel is demanding and may require reconstructions 
with microvascular musclefl aps (Tukiainen et al. 2006). 
We did not note a predictive effect of the different UTWCS classes on 
the ulcer healing time. The outcome did not signifi cantly deteriorate with 
increasing stage or grade. Oyibo et al. (2001) reported that the higher the 
stage measured with the UTWCS is at presentation, the less likely it is for 
the lesion to heal. Amputation rates have shown correlation with increasing 
UTWCS class in the studies by Oyibo et al. and Armstrong et al. (1998). One 
explanation for why we did not note similar associations could be that every 
patient in our study had a revascularisation to treat the ischaemia. In the study 
by Oyibo and colleagues less than one fourth of the patients with ischaemia, 
underwent a revascularisation. Armstrong et al. did not report any information 
about vascular procedures. This suggests that revascularisation is a more 
important predictor for healing of the tissue defects and for leg salvage than 
the depth of the lesion and presence of infection. Infection as indicated by 
C-reactive protein (CRP) has been reported to predict leg salvage after IBS in 
patients with rest pain or ischaemic tissue loss (Biancari et al. 1999, Mätzke 
et al. 2001). In addition to revascularisation, active surgical debridgement of 
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the ischaemic tissue defects, proper timing of local surgery in association with 
proper antibiotic therapy may enhance leg salvage rates and ulcer healing. 
Half of the patients in the present study underwent twice local ulcer surgery 
on average. 
Patients with gangrene did not show a prolonged ulcer healing time as 
compared to ischaemic ulcers without gangrene but gangrene turned out 
to be an independent risk factor for major amputation. These results can 
be interpreted to indicate that if the gangrenous lesion does not heal these 
patients may have a major amputation more often than patients with ischaemic 
ulcers. 
The duration of the ischemic tissue lesion did not play a signifi cant role in 
predicting ulcer healing time. Our result is consistent with the study by Mätzke 
(2004), who did not note any correlation between the duration of CLI and major 
amputation (2004). An explanation for the lack of correlation between ulcer 
duration and ulcer healing time, as well as leg salvage, could be the differences 
in the severity of ischaemia. The degree of ischaemia is likely to infl uence the 
progression of the tissue defect. 
Amputation-free survival
AFS is regarded as one of the most important outcome in the treatment 
of patients with PAD (Norgren et al. 2010). AFS was low in the present 
study mainly due to the high mortality. Our study revealed that several co-
morbidities of the CLI patients were independent risk factors for loss of life 
or limb. CLI tends to occur late in life, and a considerable part of the patients 
in our cohort were over 75 years old, which might explain the association of 
age with decreased survival and AFS. Furthermore, the follow-up lasted for 
up to ten years. Patients with gangrene had poorer AFS than patients with 
ischaemic ulcers in the present study. Many studies, which have evaluated 
the prognosis of infrainguinal bypass grafts have not analysed the role of 
the indication for leg salvage surgery (Nasr et al. 2003). Gangrene has been 
recognized to predict poor outcome also in other studies (Luther et al. 1997, 
Biancari et al. 2006, Nasr et al. 2003). Nasr and colleagues underlined the 
importance of the mode of presentation on the outcome and suggested that 
patients with gangrene should be classifi ed separately when reporting the 
results of infrainguinal bypass grafting. 
Several publications have associated renal failure with an increased risk 
for major amputation and death (Albers et al. 2007, Biancari et al. 2000). As 
patients with PAD and renal insuffi ciency share many risk factors, it is not 
surprising that patients with both diseases have high risk for cardiovascular 
and all-cause mortality (Luo et al. 2010). Amputation due to nonhealing 
tissue defects despite a patent graft occurs predominantly in the short-term 
follow-up in patients with ESRD (Albers et al. 2007). The outcome after IBS 
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in patients on dialysis is very poor, whereas the outcome is better in patients 
with renal insuffi ciency not requiring dialysis and in those with a functioning 
renal transplant (Peltonen et al. 1998).
Chronic pulmonary disease also constituted a risk factor for death and 
decreased AFS in our study. This fi nding may be a refl ection of the adverse 
effect of smoking. The infl uence of smoking on AFS was not separately 
analysed in the present study as information on smoking habits is unreliable 
(Eskelinen et al. 2005). In previous studies smoking has been associated with 
decreased graft patency and limb salvage rates (Lassila et al. 1986, Galaria et 
al. 2005). 
In the present study, diabetes was associated with poorer AFS in univariate 
analysis but diabetes was not an independent risk factor for decreased 
AFS. Some studies have shown that the clinical results following arterial 
reconstruction are worse in diabetics with an increased mortality and inferior 
leg salvage (Wölfl e et al. 2003, Malmstedt et al. 2008). A number of series, 
however, have demonstrated that with an aggressive approach, diabetic 
patients can achieve similar leg salvage and survival after revascularisation 
to non-diabetics (Gathan et al. 1998, Akbari et al. 2000, Weiss and Sumpio 
2006). The number of patients with rest pain and tissue loss in the studies 
varied, which might have caused the different results.
Redo infrainguinal bypass surgery 
The life span of the graft is highly variable, and a signifi cant percentage of grafts 
fail in subsequent years (Belkin et al. 1995, Albäck and Lepäntalo 1998, Conte 
2009). Unfortunately, the recurrence of ischaemic symptoms that accompany 
graft occlusion requires some intervention in a majority of cases. We noted a 
high major amputation rate, 50% at one year, in patients with failed grafts for 
whom redo IBS was not possible. Baldwin et al. (2004) reported equally poor 
leg salvage rate after graft failure. Management of these failed bypasses can 
be particularly challenging in a group of patients ill-suited to tolerate multiple 
operations. As secondary patency gauges the success of one bypass only, we 
preferred to evaluate the tertiary patency rate to measure the whole successful 
period with a patent graft in a revascularised leg. In the present study, the 
tertiary patency rate was superior to the secondary patency rate. This result 
may refl ect both active redo bypass surgery and the satisfactory results of the 
redo bypasses. 
We also chose to assess the patency– leg salvage gap that describes the 
proportion of leg salvage not attributable to verifi ed graft patency (Eskelinen 
and Lepäntalo 2007). In this study, the tertiary patency and leg salvage rates 
were equal. Although there may be patients who underwent major amputation 
despite a patent graft, and patients who avoided amputation despite graft 
failure, the absence of a signifi cant gap between leg salvage and tertiary 
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patency rates may indicate the importance of a patent infrainguinal graft to 
save a leg with ischaemic tissue loss. In CLI-studies the interpretation of 
the patency– leg salvage gap has turned out to be diffi cult because tertiary 
patency is seldom reported and the effect of redo bypasses is not noted in 
secondary patency (DeLuccia et al. 2008). Wide patency-leg salvage gaps are 
typical for endovascular series (Eskelinen and Lepäntalo 2007, Romiti et al. 
2008). The most probable reason for the wider patency-leg salvage gap after 
PTA is the fact that the treated legs have milder ischaemia than those treated 
by IBS (Norgren et al. 2007). Other reasons could be that only a part of 
endovascularly treated arterial segments reoccludes or that the performance 
of additional surgical and endovascular interventions affect the outcome 
(Romiti et al. 2008).
Infrapopliteal bypass vs. PTA
During the last decade, endovascular treatment has been introduced with 
increasing frequency for the treatment of arterial occlusive disease even in the 
most challenging target areas such as the infrapopliteal segment. Low rates 
of early morbidity have been considered an advantage of PTA as compared 
to IBS in the management of severe limb ischaemia (BASIL trial participants 
2005). The comparison of surgical and endovascular techniques in randomised 
controlled trials is almost impossible due to diffi culties in forming comparable 
groups. Moreover, in retrospective studies, the patient characteristics for 
surgical and endovascular groups may differ signifi cantly. In order to avoid 
the diffi culties of comparing “apples and oranges”, propensity score analysis 
may be used to adjust for such important differences (D’Agostino 1998). Our 
propensity score analysis included preoperative risk factors, indications for 
the procedure as well as leg status, target segment, previous revascularisation 
procedure on the same segment, and patent target vessel down to the pedal 
artery. In the overall series and in the propensity score matched pairs PTA 
and bypass surgery achieved similar 5-year leg salvage, survival and AFS 
rates. The BASIL trial demonstrated similar AFS at 3 years after infrainguinal 
PTA and bypass, but in patients surviving longer than 2 years bypass was 
associated with a signifi cant increase in survival and a trend towards improved 
AFS (Bradbury et al. 2010). The BASIL trial showed that there was a greater 
need for additional procedures after an endovascular approach than after 
bypass surgery. Although the need for extra procedures was not higher after 
the endovascular approach in the present series, the need for additional bypass 
was markedly higher in the endovascular group, indicating poorer patency for 
the endovascular approach. This may also explain the lower major amputation 
rate in the isolated infrapopliteal subgroup for PTA. Active redo surgery 
therefore appeared to improve the outcome. 
A real problem in treating lower limb ischaemia and trying to compare 
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different modes of treatment is that it is very diffi cult to standardise the disease 
treated. Even when propensity score analysis is applied, the comparison of 
bypass and PTA still faces this problem - the type of the treated lesion and the 
extent of arterial disease were not taken into account due to the lack of proper 
classifi cation of infrapopliteal lesions. There are a number of infrainguinal 
arterial lesions that are not easily classifi able, and current classifi cation systems 
are reported to have poor reproducibility (Koelemay et al. 2001, Kukkonen 
et al. 2010, Zimmermann et al. 2010). Moreover, endovascular interventions 
are much more likely to be performed for stenotic segments than occlusions 
(Norgren et al. 2007). As bypass surgery is particularly suitable for longer 
lesions, the incomparability of the segments treated may have infl uenced 
the present results. As previous randomised trials have demonstrated, only 
4-29% of the lesions have been treatable by either method (the BASIL trial 
participants 2007, Lepäntalo et al. 2009), which worsens the generalisability 
of the fi ndings of randomised controlled trials. The strength of a registry-
based study is the large coverage of patients in daily practice. Bypass and 
endovascular interventions can be considered complementary rather than 
competitive techniques in infrainguinal revascularisation.
Multidrug resistant Pseudomonas aeruginosa
Antimicrobial resistant pathogens are increasingly involved in vascular 
surgical site infections (Bandyk 2008). Wound and graft infections are 
potentially life- and limb-threatening complications in vascular surgery. The 
consequences of multidrug resistant P. aeruginosa outbreaks among intensive 
care unit (Agodi et al. 2007) and transplantation unit patients (Lyytikäinen 
et al. 2001) have been studied but to our knowledge this is the fi rst study 
analysing the consequences of a MDR Pa outbreak among patients with CLI. 
We noted a considerably AFS at one year after infrainguinal bypass grafting 
in the MDR Pa group compared to the control group. The most vulnerable 
patients with MDR Pa died early after the IBS or were apt to have a major 
amputation soon after reconstruction due to nonhealing ischaemic tissue 
defect or incisional wounds. Later on during the follow-up, the differences 
in the AFS rates between the MDR Pa and control group disappeared. The 
explanation behind the lack of infl uence of the MDR Pa on long-term follow-
up may be that the overall long-term survival of CLI patients is low. The 
increased frequency of local surgical procedures to the incisional wounds and 
ischaemic tissue defects in the MDR Pa group may refect the limited means of 
effectively treating MDR Pa with antimicrobic agents. As almost in half of the 
control group a non-multidrug resistant P. aeruginosa was cultured from the 
ischaemic lesions or incisional wounds, our study indicates that the multi-drug 
resistant character of P. aeruginosa has a crucial role for the decreased short-
term AFS. The greatest problem during the outbreak was the identifi cation of 
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the source of the MDR Pa, which remained obscure despite several intensive 
attempts to track the origin.
Improving outcome after IBS
Optimising the wound care may be a tool to shorten the healing time. The 
wound care in this study was not standardised and occurred partly within 
primary health care. In Denmark, the initial results of establishing of a 
multidisciplinary woundhealing centre have demonstrated improved healing 
rates of leg ulcers (Gottrup 2004). A specialised woundhealing centre that 
includes an outpatient clinic as well as an inpatient ward would be needed 
to optimise the treatment of problem wounds. Standardised diagnostic and 
treatment plans, a higher degree of continuity in treatment, access to surgical 
approaches and integration of multiple specialists in a woundhealing centre 
would contribute to improved wound care.
Patient selection may be a tool to improve survival, as well as AFS after IBS. 
However, over the last decades a more active reconstruction policy has yielded 
regional decrease in major amputation rates in patients with CLI (Holstein 
et al. 2000, Luther et al. 2000, Eskelinen et al. 2004). Despite the need for 
repeat surgery, reconstructive surgery has been found to be cost-effective in 
potentially mobile patients who are likely to regain their independent living 
status compared with major amputation (Luther 1997). Different risk scores 
for CLI patients have been developed to predict AFS after revascularisation 
(Biancari et al. 2006, Schanzer et al. 2008). These scoring methods have turned 
out to be reliable in large cohorts, but on an individual basis the situation 
may be different. Besides comorbidities, graft material, outfl ow status, 
revascularisation policy and a multidisciplinary approach have an important 
impact on the outcome of these patients (Albäck and Lepäntalo 1998, Biancari 
et al. 2000, Eskelinen et al. 2004, Biancari et al. 2007). 
Improvements in surgical techniques, anesthesia and perioperative care 
may be able to reduce the immediate postoperative mortality (Nehler et al. 
2003), but they may not considerably affect the long-term mortality. Due to 
surgical and anesthetic evolutions, it is possible to treat patients with increased 
comorbidities and more advanced leg ischaemia (Conte et al. 2001). As a 
result, the postoperative outcome may not change. Risk factor management 
may be another tool to improve survival after IBS. The question is whether 
aggressive risk factor management in patients with CLI and tissue loss will be 
able to improve the long-term survival of the patients, or whether they have 
such extensive atherosclerosis that their mortality risk can not signifi cantly be 
modifi ed. 
There is no consensus regarding the most appropriate endpoint in the evaluation 
of CLI-patients, and reporting standards do not defi ne any standard period of 
observation. Furthermore, the patient and the clinician may have different views 
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as to what constitutes success. The adoption of rigid guidelines to determine which 
patient should be offered surgical intervention would be ill advised. IBS surgery 
may be justifi ed in these high-risk potentially mobile patients with ischaemic tissue 
loss, since most of the patients have no other alternatives for major amputation. 
A successful intervention offers an opportunity to relieve suffering and preserve 
mobility. 
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11. CONCLUSIONS
1. Complete ulcer healing, including the healing of the ischaemic tissue 
defects and incisional wounds, is a slow process. Diabetes prolonged the 
complete ulcer healing time. Ischaemic tissue defects located in the mid-
and hindfoot healed poorly. Half of the patients had achieved complete 
ulcer healing and were alive with a salvaged leg at one year after IBS. 
2. Infrainguinal bypass grafting in patients with ischaemic tissue loss resulted 
in a high rate of leg salvage but the life expectancy of the patients was 
poor. 
3. Redo infrainguinal bypass surgery resulted in a signifi cantly higher tertiary 
than secondary graft patency rate. This might refl ect active leg salvage 
surgery with satisfactory results. The absence of gap between tertiary 
patency rate and leg salvage rates indicates the importance of a patent 
infrainguinal bypass graft to save a leg with ischaemic tissue defects.
4. When feasible, infrapopliteal endovascular revascularisation as a fi rst-line 
strategy is expected to achieve similar long-term results to bypass surgery 
in CLI when redo surgery is actively utilized. As feasibility issues related 
to the segment treated could not be analysed separately, the results cannot 
be generalised to represent the applicability of PTA fi rst strategy in all 
infrapopliteal lesions.
5. MDR Pa in a patient with CLI should be considered as a serious event with 
high risk of early major amputation or death.
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